網頁

醫藥 - 哈爾濱工業大學生命科學中心招聘會 11/15

哈尔滨工业大学生命科学中心招聘宣讲会暨经验交流会
How to succeed in starting a biomedical lab in China
 
主讲人:黄志伟 教授
(生命科学中心主任,生命科学与技术学院院长   
                       
Time: 18:00 – 20:00 pm, Nov 15th (Fri.), 2019
Location: Room 308/309, Smith Building, Dana-Farber Cancer Institute
450 Brookline Ave, Boston, MA 02115
(Dinner will be served)
 
主讲人介绍:
黄志伟,哈尔滨工业大学教授。生命科学中心主任,生命科学与技术学院院长。长江学者奖励计划特聘教授,国家杰出青年科学基金获得者,获中国青年科技奖和谈家桢生命科学创新奖。入选哈尔滨工业大学首批青年科学家工作室。

研究方向:
1. 宿主免疫防御与微生物感染的分子机制;
2. 人适应性免疫系统的分子机制;
3. 人体微生态系统及相关疾病的机制;
4. 研发新型CRISPR-Cas基因编辑工具进行遗传病等的治疗应用。

Zhiwei Huang is a Professor of Harbin Institute of Technology (HIT), Director of The HIT Center for Life Sciences, Dean of School of Life Science and Technology. He was appointed as the distinguished professor of the Yangtze River Scholar Award Program of the Ministry of Education. He was awarded with The National Science Fund for Distinguished Young Scholars, China Youth Science and Technology Award, Tan Jiazhen Life Science Innovation Award. He was selected the first batch of Young Scientist Lab of HIT.
Research Area:
1. Dissecting the molecular mechanisms involved in host immune defenses and microbial infection.
2. Dissecting the molecular mechanisms involved in human adaptive immune system. 
3. Investigating the underlying mechanisms of microbial dysbiosis in human diseases.
4. Developing novel CRISPR-Cas genome editing tools for the treatment of genetic disorders.

(陶建立 萧安)
-------------------------
以下转载自 HIT生命科学 公众号,

哈尔滨工业大学生命科学中心成立于2016年,试点进行基础科学研究、人才培养一体的体制机制综合改革与创新。在2020US News世界大学排名中,哈尔滨工业大学生物学与生物化学全国排名第9。作为哈尔滨工业大学首个学术特区,生命科学中心具有相对独立的学术、人事和财务自主权以及研究生培养体系,运行与国际接轨的基础科研管理机制。
目前已经有多位优秀PI入职并开展工作,在未来五年内我们将继续招聘多名在结构生物学、肿瘤生物学、神经生物学、生物化学与分子生物物理学、微生物与免疫学、化学生物学等基础生物医学研究领域有建树、有潜力的青年科学家,为其提供有足够竞争力的研究设施、配套经费和生活保障,助力青年科学家快速成长,力争在较短时间内使生命科学中心发展成为国际一流的生命科学研究机构。

20191115日、1116日(美国当地时间),生命科学中心主任黄志伟教授将分别在波士顿、休斯敦进行人才招聘宣讲。

招聘方向:
神经科学、微生物与免疫学、生物物理与结构生物学(冷冻电镜方向)、癌症生物学、化学生物学、纳米生物材料和细胞组织工程、蛋白质组、DNA损伤与修复、基因编辑,以及与人类疾病相关的基础研究及转化应用领域。

应聘条件:
博士学位以及多年博士后或独立科研工作经验,在近几年内发表具有国际影响力的学术论文,能够独立开展创新性研究,并具备几年内达到该学科国际一流水平的潜力。

条件待遇:
1.实验室空间:提供≥150平米的独立实验和办公空间;
2.启动资金:提供1000万元的研究经费支持,用于实验室试剂、耗材、人员聘用、小型设备的购置等;
3.PI年薪(税前):≥45万元;
4.安家费:A类:110万元,B类:60万元;
5.研究生名额及实验室人员招聘政策倾斜;
6.子女入托入学,配偶安排工作等相关校内福利。

考核评价:
采取合同制,聘期五年,聘期结束进行国际同行评估,聘期评估合格取得永久职位,否则不再续聘。

联系方式:
申请者需将求职信一封、个人详细简历、发表的论文、三个推荐人姓名及联系方式和研究计划一份,发至huangzhiwei@hit.edu.cn。招聘一直有效,直至招满。


主讲人
黄志伟
哈尔滨工业大学教授
生命科学中心主任
生命科学与技术学院院长
国家杰出青年科学基金获得者,入选教育部长江学者奖励计划新世纪优秀人才计划,获中国青年科技奖和谈家桢生命科学创新奖。入选哈尔滨工业大学首批青年科学家工作室。

哈尔滨工业大学生命科学中心期待您的加入!
Special Talk//台灣大學農學院 盧虎生 院長:台灣農業的現況: 生物經濟及智慧農業
Friday, November 15, 2019 at 5:30 PM – 7:30 PM EST
TMEC 250 mini amphitheater, 260 Longwood Ave, Boston, MA 02115

*講者: 臺灣大學生物資源暨農農學院長盧虎生教授
*講題: 台灣農業的現況: 生物經濟及智慧農業

*時間: 11/15/19 (Fri) 5:30 pm

*地點: Harvard Medical School TMEC 250 Mini amphitheater

(260 Longwood Ave, Boston, MA 02115)
http://www.bioagri.ntu.edu.tw/cbaintro03.php
*提供簡單茶水點心

(感謝TECO贊助協辦)

哈佛医学院华人专家学者联合会 
Chinese Scientists and Scholars Association at Harvard Medical School
HMS-CSSA
微信公众号: hmscssa
HMS-CSSA助手微信号:hmscssa2007
(添加好友后可由助手号邀请加入 HMS-CSSA 学术群、HMS-CSSA 生活群)

2019美中生物医药协会投资创业论坛

 Jo Lee CABA
2019美中生物医药协会投资创业论坛
2019 Chinese-American BioMedical Association (CABA) Investment and Entrepreneurship (IE) Symposium
2019年9月28日(周六)美东时间早上8点 
Boston Marriott Newton 
2345 Commonwealth Avenue 
Newton, Massachusetts 02466 USA
活动介绍
2019美中生物医药协会投资创业论坛又将如期登陆波城,现论坛诚邀各位怀揣热情的投资人及创业者共同参与。自2008年起,IE论坛已经连续多年于波城举办并且取得圆满成功。我们持续与生物制药创业公司和投资者携手合作,发掘并推动制药领域的投资创业。此次IE论坛,我们再次邀请到多位来自工业界和学术界的专家,以及资深的投资人和律师,就生物制药领域的一系列前沿话题进行交流探讨,并提供针对行业现状及未来趋势的重要见解。
Nandita Shangari, Ph.D.       Principle, Novartis Venture Fund
Brian Gallagher, Ph.D.   Partner, Abingworth
Hong Cheng, Ph.D.     Head of Research Strategy, Sanofi
Lixin Shen, Ph.D.     Founder and Chief Executive Officer, Guangzhou Alagen PharmTech
Yihan Wang, Ph.D. Founder and Chief Executive Officer, Shenzhen TargetRx, Inc.
Yongzhong Wang, Ph.D.      Chief Executive Officer, CMAB Biopharma
Linda Ji, J.D.     Partner, McDermott Will & Emery
Hugh Davis, Ph.D. Chief Business Officer, Frontage Laboratories, Inc
Jens Stephan, Ph.D.      Professor, East Michigan University
Dapeng Sun, Ph.D. Chief Technology Officer, ABclonal Technology
John Giszczak Vice President, Business Development MORE Health
Shaoyu Chang, M.D.    Vice President, FC Capital
Pengpeng Li, Ph.D.  Analyst, 5AM Ventures
Joe Zhou, MBA  Fouding Partner, BAC Investment
Hongkai He      Venture Partner, Skylight Investment
Jianying Shi, Ph.D.  Vice President, HD Biopharmaceuticals
Michael Zhao    Founder, QTang Ventures
CABA is a 501(C)(3) not-for-profit professional organization registered in Massachusetts since May 2007. CABA is committed to promote public awareness of advancement in the pharmaceutical and biomedical industry, professional interactions in the fields of life sciences, global biomedical innovations and business development.
Chinese-American BioMedical Association
The 2019 BTBA symposium will be held on August 3-4th at Harvard University Northwest Science Building, Cambridge, MA. This event will feature more than 20 speakers, including experts who lead clinical development activities in human diseases, and professionals in the field of gene regulation and molecular immunology. We have crafted an agenda that includes inspiring presentations and interactive forums focused on the novel technologies in synthetic biology, penetrating insights into biotech environments around the US and practical experiences about how to survive in academia/industry. No matter you are biotech entrepreneurs, professionals or students, you can find what you need to advance your future career in here. Please join our annual symposium by registering here>>>

👉👉👉👉👉Ticket: https://www.eventbrite.com/e/btba-annual-symposium-tickets-62120152047?fbclid=IwAR0lv0YFyLwqTqeEv_NcEUrwqFvqDlX8QX3RK5ysjAaTjeusW-Url-qrHGA

👍👍For more information, please visit our website: http://btbatw.org/2019/website


一年一度的BTBA symposium開放售票囉!!
來自各個領域的專家 數十載企業實戰經驗 透徹犀利的職場分析 全部無私分享給你
還在等甚麼,還不趕快來報名!!!!!!!
時間: 2019 Aug 3-4th
地點: Harvard University Northwest Science Building
🎈🎈🎈報名連結: https://www.eventbrite.com/e/btba-annual-symposium-tickets-62120152047?fbclid=IwAR0lv0YFyLwqTqeEv_NcEUrwqFvqDlX8QX3RK5ysjAaTjeusW-Url-qrHGA

2019 SAPA-NE 21st Annual Conference
Deliver Optimal Medicines to All Patients
(Boston Cambridge Marriott, June 8th, 2019)

秉承20年发展壮大的辉煌,胸怀治愈人类疾患的梦想,新英格兰美中医药开发协会SAPA-NE将于2019年06月08日在Boston Marriott Cambridge 宾馆 (50 Broadway, Cambridge, MA) 隆重举行第21届年会。届时,学术精英、企业领袖、投资英才、药界同仁等将云集全球医药创新的圣地—波士顿剑桥,围绕Developing and Delivering the Advanced Medicines to All Patients 的会议主题展开学术交流、共同探讨人类医药事业发展之未来。欢迎光临,敬请注册。
更多详情:https://www.sapa-neweb.org/ac2019 
注册链接(早鸟截至日期:5/17/2019):https://www.sapa-neweb.org/ac2019event
Upcoming Event: 2019-06-08 SAPA-NE 21st Annual Conference: Deliver Optimal Medicines to All Patients
Selected keynote speakers:
* Edward Hu, Co-CEO, WUXI AppTec
* Sridaran Natesan, PhD, Vice President, Sanofi
* X. Shirley Liu, PhD, Professor at Dana–Farber Cancer Institute and Harvard T.H. Chan School of Public Health
* Brad Loncar, CEO, Loncar Investments
* Shi Wenzhao, President of Digital China Health Technologies Corporation Limited
* Shaun R. Coughlin, MD, PhD, VP, Global Head of Cardiovascular and Metabolism at Novartis
SAPA-NE 2019 年会将集中探讨医药行业前沿,热门人工智能,大数据分析,先进肿瘤免疫疗法,多重治疗模式,等等话题。会议还将组织CEO论坛,与大家面对面分享经验。精彩不容错过,欢迎光临,敬请注册:https://www.sapa-neweb.org/ac2019 (早鸟截至日期:5/17/2019:https://www.sapa-neweb.org/ac2019event )
Speaker介绍:Gregory Verdine博士
FogPharma由生物技术领域知名连续创业家、哈佛大学终身教授Gregory Verdine博士创立。这家新锐公司致力于突破现有的常规手段,找到全新的新药分子。其核心技术是Verdine教授在哈佛大学研发的新型技术- 可穿透细胞的迷你蛋白(CPMP)。它有望靶向“不可成药”的靶点,为新药发现与研发带来变革。

除了FogPharma之外,Greg Verdine博士还创办并领导了LifeMine Therapeutics,该公司创建了首个基于真菌基因组的药物开发平台,可以高效快速开发新药。LifeMine Therapeutics和FogPharma总部都设在马萨诸塞州剑桥,并于2016年成立。Verdine博士因其在生涯中担任生命科学家,企业家,投资人和首席执行官的成功角色而得到高度评价。他是哈佛大学和哈佛医学院的Erving教授,先后创建了多家纳斯达克上市的生物技术公司,包括Wave LifeSciences,Enanta,Eleven Bio,Variagenics,Tokai,Aileron和一家私有公司Gloucester制药公司,由Celgene于2010年收购。





Sino-American Pharmaceutical Professionals Association
New England (SAPA-NE)
High School Excellence Scholarship Program

Eligibility
The applicant must meet the following criteria:
  1. The applicant must be a United States citizen or legal resident alien residing in the New England area (MA, NH, RI, VT, CT, ME).
  2. The applicant must be a graduating high school senior with a GPA of 3.3 (out of 4.0) or greater and an SAT score above 1450 (out of 1600) or equivalent.
  3. The applicant must be enrolling for the first time in a full-time undergraduate course of study at an accredited 4-year college or university in the upcoming academic year. The applicant should pursue or intend to pursue a major related to life sciences.
  4. Members of SAPA-NE Board of Directors, the SAPA-NE Advisory Committee, or the SAPA-NE Scholarship Selection Committee cannot participate on the selection process. Any member of the SAPA-NE Executive Committee must disclose should his or her relative become an applicant. Failure to disclose a position of conflict of interest will not only disqualify the candidate, but also lead to disciplinary action towards the executive member.

Application procedures
Application materials
The applicant must submit:
  1. A brief resume illustrating major accomplishments during the applicant’s K-12 education
  2. An essay (~600 words) to illustrate what the applicant will be pursuing at college and what inspired him or her to make such a decision
  3. A recommendation letter from the school counselor and two letters of recommendation from teachers who can attest and comment on the applicant's achievements and development potentials
  4. A copy of high school transcript and a copy of standard test results.
  5. A copy of acceptance letter from the college the applicant intends to enroll
  6. An application fee ($30) needs to be submitted along with the application. Please make any checks payable to SAPA-NE. The application fee can be waived if the applicant’s parent or legal guardian is a member of SAPA.

Online application form is available: http://www.sapa-neweb.org/scholarship-application/. You may fill in the online application form, print the application, and send the application along with recommendation letters, a copy of acceptance letter from the college, and application fee to the following address.
Application Deadline
May 17, 2019 (Postmarked)
Application Mail Address:
Please enclose ALL the materials, including sealed recommendation letters, in ONE package and send to SAPA-NE:
SAPA-NE High School Excellence Scholarship
12 Arbor Lane, Winchester MA 01890
Email Addresses:
Please notify Drs. Huo Li and Guiqing Liang after you send out the application
Huo Li: huoli2@gmail.com;  Guiqing Liang: lianggq1@gmail.com
Selection Procedures
An independent Scholarship Selection Committee appointed by the SAPA-NE Executive Committee will evaluate all valid applications and nominate several strongest candidates. SAPA-NE Executive Committee will make the final selection of up to three award recipients.
Applicants will be evaluated on:
  1. Academic performance, leadership quality, and community/school service.
  2. Demonstrated potential and commitment to a career aspiration that has a broad impact in the society.
Award Acceptance
Recipients of 2019 SAPA-NE High School Excellence Scholarship will be notified by Scholarship Selection Committee by email and will also be posted at SAPA-NE homepage http://www.sapa-neweb.org/scholarship.

Upon contact by Scholarship Selection Committee, a SAPA-NE Scholar must submit an acknowledgment letter stating the acceptance of the scholarship award. The recipients (required) and their parents/legal guardians (optional) will attend the 2019 SAPA-NE High School Excellence Scholarship Award Ceremony at 21st SAPA-NE Annual Conference on June 8, 2019 at Boston Marriott Cambridge, Cambridge MA. A short speech (5 minutes) made by each award recipient will be expected at the ceremony. Each recipient will be awarded up to $1000 one-time scholarship.
2019 Boston BioForum (CABA) Driving Transformation in Life Sciences Industry
2019波士顿生物医药论坛| CABA
Date and time: Saturday, May 4, 2019 @ 8AM EST
The Westin Waltham Boston
70 3rd Ave, Waltham, MA 02451

The goal of the annual conference is to invite prominent entrepreneurs, investors, biotech and pharma executives, academic and industry scientists, as well as professionals from the legal, finance, and healthcare fields to talk about hot topics in the Life Science industry.
  • Future of Immuno-Oncology
  • Outlook of Cell & Gene Therapy
  • AI & Big Data in Health
  • Evolving Landscape for Life Science Investment
  • Next Big Thing in Biotech & Pharma
Speakers

  • Will Brownsberger
    MA State Senator

  • Jos Melenhorst
    Director, CAR-T Product Development
    University of Pennsylvania

  • Jonathan Terrett
    Head of Immuno-Oncology
    CRISPR Therapeutics

  • Sadik Kassim
    Executive Director
    Kite Pharma

  • Nenard Grmusa
    SVP, Head of External Innovation
    Takeda

  • Lei Xiao
    CEO
    Innovative Cellular Therapeutics

  • Derrick Li
    Head of Strategy and Investor Relations
    Cellular Biomedicine Group

  • Nick Valiante
    Founder and CEO
    Glyde Bio

  • F. Stephen Hodi
    Directot, Center for IO
    Dana Farber Cancer Institute, Harvard Medical School

  • William Cao
    CEO
    GraCell Bio

  • Weichang Zhou
    Chief Technology Officer
    Wuxi Biologics

  • Scott Brown
    Director
    Computational Chemistry
    Sunovian

  • Catherine Sabatos-Peyton
    Direcctor
    Novartis Institutes for BioMedical Research

2019年哈佛华人生物医学年会

 HMS-CSSA HMSCSSA 3/23

欢迎大家参加哈佛大学2019年华人生物医学年会!本次学术年会将于4月28日(周日)在波士顿儿童医院召开 。参会报名请见文末注册链接(.edu 邮箱注册免费)。

哈佛华人生物医学年会学术论坛自2009年举办以来,每次都吸引了数百名来自中国和美国学者参加,已成为中美生命科学和医学领域重要的学术会议之一。今年的学术论坛恰逢此学术盛会十周年,将覆盖从基础研究到肿瘤治疗,从技术创新到临床应用的最新进展,涵盖肿瘤免疫学、表观遗传学、神经学、转化医学等多个热门和前沿课题。

邀请的十位演讲嘉宾包括:
(图片可轻按放大)

姓名
单位、职务
研究方向
施扬
哈佛医学院,波士顿儿童医院
可控的表观遗传机制和转录调节因子
Harvey Lodish
麻省理工学院生物工程系、Whitehead研究所创始成员;美国科学院院士,《分子细胞》作者
红血细胞,脂肪细胞功能及生物疗法应用;长链非编码RNA功能
何志刚
哈佛医学院、波士顿儿童医院
中枢神经系统损伤和其他神经系统功能的恢复
Ed Boyden
麻省理工学院、神经技术学
复杂生物(大脑)系统和功能的修复
任兵
加州大学圣地亚哥分校基因组医学研究所
人类胚胎干细胞分化和哺乳动物发育的基因组、表观基因组的分析
袁国丞
哈佛陈曾熙公共卫生学院、丹娜-法伯癌症研究所
计算生物学与生物信息学基因组分析以理解基因调控机制
蔡理慧
麻省理工学院Picower学习与记忆研究所所长
神经修复与阿尔兹海默症
冯国平
麻省理工学院大脑与认知科学系
神经突触和环路功能及精神疾病发生机理
刘勇军
赛诺飞研发高级副总裁兼全球研究负责人
肿瘤免疫转化医学
陈建柱
麻省理工学院生物学系
免疫记忆,抗肿瘤T细胞反应;人源小鼠模型的建立和应用

除了演讲之外,我们还会和CAHON(www.cahon.org; 美国华裔血液和肿瘤专家学会)一起组织一个 Immuno-oncology Panel Discussion和大家就最新的热点领域进行交流

(图片可轻按放大)

年会上我们还会颁发2019年度哈佛杰出华人生命科学研究奖(Harvard Chinese Life Science Annual Distinguished Research Award),欢迎大家自行报名或提名朋友同事,具体信息请参见下一篇公众号文章内容。














The Harvard Chinese Life Science Annual Symposium (HCLS) is the signature event organized by HMS-CSSA. The symposium covers basic life science research, translational medicine, and biopharmaceutical industries. It draws hundreds of attendees working in life science-related areas in the U.S. and China.


Time:
Sunday, April 28th, 8:30 AM - 5:00 PM

Location: 
Folkman Auditorium, Ender's Building
Boston Children's Hospital
320 Longwood Ave, Boston, MA 02115


























年度盛会,精彩内容,诚邀您的参与。


长按识别以下二维码进行注册(或点击文末“阅读原文/Read more”)
Refreshment and lunch will be provided with RSVP! 


















































HMS-CSSA is a non-profit organization operated by volunteers who are full-time postdocs, students or visiting scholars at Harvard Medical School and its affiliated hospitals. We aim to create a platform for networking, cooperation, and career development among our members, hence serving as a bridge for intercultural communication between China and US.
This year’s event is the 10th  annual meeting organized by HMS-CSSA, and HCLS Annual Symposium has become more influential and more recognized and appreciated by the HMS Chinese community during the years. Every year, more than 500 people register and attend the one-day-long symposium in person or watch the live broadcast online. Last year, Dr. George Daley, Dean of Harvard Medical School, gave the opening remarks. Last few years’ speakers include Lieping Chen, Gordon Freeman, Xiaoliang Sunney Xie, Chuan He, Shirley Liu, Matthew Meyerson, Yang Shi, Hao Wu, Kai Wucherpfennig,Tian Xu, Junying Yuan, Feng Zhang, etc.  
The 2019 symposium will be equally exciting that Dr. Harvey Lodish, Dr. Yang Shi and Dr. Yongjun Liu etc. have accepted our invitation. We sincerely invite you join us! Your presence will make this year's program more exciting with more impact! 


















文案:唐爽 梁丹 祁亚楠 萧安 岳宏
编辑排版:萧安 李江

【YSA x Z-Park】构建精准医疗未来版图(Frontiers in Precision Medicine)

YSA 青年学者联盟YSA 2 days ago
















点击青年学者联盟YSA关注公众号

本期的Frontiers系列的话题是精准医疗(Precision Medicine),YSA和Z-Park有幸邀请到精准医疗领域优秀的企业家来给大家分享构建精准医疗未来版图。

With dramatic decreases in cost andturn-around time, next-generation sequencing (NGS) has become a powerful tool for basic research and various clinical applications. From the study of disease mechanisms to the search for predictive biomarkers to the design of personalized cancer vaccines, NGS is increasingly employed in applications of precision medicine.

Speakers:

Jeff Cheng, Ph.D.
Chief Scientific Officer at Novogene

Talk title: Leading Edge Next-Generation Sequencing and Bioinformatics Services

Jeff Cheng, PhD, is currently the Chief Scientific Officer and Global Head of Biopharmaceutical Services at Novogene Corporation, a global next-generation sequencing and bioinformatics provider.

Prior to joining Novogene, Jeff was the Biomarker Science Leader and China Site Head in the Department of Oncology Biomarker Development at Genentech and Roche Product Development in Asia Pacific. Before that, he was the Head of Scientific Liaison for Biomarker Research at Roche Pharmaceuticals in Shanghai and a Principal Investigator of In Vivo Oncology at BeiGene among other positions.

Jeff obtained his Bachelor’s degree in Chemical Engineering from Tsinghua University in Beijing, China. He then went to Rice University for his PhD in Chemical and Biomolecular Engineering which was followed by a post-doctoral research fellowship at Massachusetts General Hospital and Harvard Medical School. His research there was focused on vascular biology and tumor micro-environment.

Mark Driscoll, Ph.D.
Co-founder and CSO at Shoreline Biome

Mark’s talk will present data that the combination of lysis, PCR design, long readamplicon, and database are key to identifying microbial strains that influence human health.

Dr. Mark Driscoll has led and supported teams launching transformative new sequencing innovations globally since 2000, including teams at 454 Life Sciences that launched the GS20, GS FLX, and the GS Junior Next Generation Sequencing systems. Mark has experience leading the development of hardware, software, informatics and reagents supporting transformative NGS technology advancements.  As a co-founder and CSO of Shoreline Biome, Mark has been instrumental in the development of their high throughput DNA preparation and rRNA amplicon NGS kits, including the first all-in-one 16S-23S long read Amplicon kit and 16S-23S database, that, in combination with the PacBio sequencing system, enables differentiation of closely related bacterial strains using high-throughput, long read rRNA gene sequencing. Dr. Driscoll received his Ph.D. in Biochemistry from the University of Rochester.

About Novogene:

As the world’s largest NGS service provider, Novogene offers research, pre-clinical and clinical scientists abroad array of sequencing and bioinformatics services, including whole genome and exome sequencing, targeted panel sequencing, RNA sequencing, single cell sequencing and microbiome sequencing, for a wide spectrum of sample types. To date, we have:
  • The largest sequencing capacity in the world with: 27-Illumina NovaSeq, 30-Illumina HiSeq X, 20-PacBio Sequels, 5 Thermo Fisher Ion S5XL, and more!
  • Completed nearly 20,000 projects
  • Sequenced 3,700,000 samples for more than 10,000 global customers
  • Analyzed more than 500,000 biological samples (in 2017 alone!)
  • Published over 1,850 customer research papers in top publications, like Nature and Science
  • Accumulated approximately 50 NGS-related patents

In addition, Novogene has developed and validated several clinical-grade oncology assays for precision medicine following strict quality control standards to ensure the highest data quality. These include:
  • NovoFocus™ NSCLC CDx – A CFDA-approved 26-gene companion diagnostic assay for patients with non-small cell lung cancer
  • NovoFocus™ PARPi CDx – An analytically validated 45-gene companion diagnostic assay for patients who may benefit from PARP inhibitor treatment
  • NovoPM™ - A ~500-gene comprehensive genomic profiling panel for solid tumors
  • NovoNeoantigen™ - A robust bioinformatics pipeline for cancer neo-antigens identification using whole exome sequencing and whole transcriptome sequencing data from paired tumor-normal samples

Novogene is fully committed to helping you meet your drug R&D goals with our state-of-the-art sequencing facilities, unparalleled scale, efficiency, quality, and price.

About Shoreline Biome:

Shoreline Biome is a start-up company witha passion for developing innovative discovery technologies for the microbiomeand bringing these products to market.

Shoreline Biome has created discovery tools that are advancing the leading edge of understanding how the human microbiome functions across the entire landscape of human health and disease. The initial products from Shoreline Biome, are the first DNA sequencing assays to comprehensively, rapidly, and inexpensively identify all members of the microbiome down to the subspecies or strain level. These results are achieved through our superior cell breaking technology and rational product design. Our companion analysis software enables straight forward identification and quantitation of all of the bacteria in microbiome samples.

Event location: 1000 Massachusetts Ave,Cambridge, MA 02138

Event time: Time: 5:30pm-7:30pm,Thursday, April-18-2019
(Pizza will be served)

Please scan the QR code to register:
Thank you for the full sponsorship from Novogene!
















关于Z-Park中关村创新中心

Z-Park中关村创新中心 致力于搭建中美科技创新交流的桥梁, 中关村海外创新平台汇聚北美高精尖创新创业资源, 合作于众多知名投资基金、创业导师及学术专家,提供孵化加速、跨境培训、分析咨询为一体的专业服务。中关村帮助美国企业家和创业者在中国开拓市场,同时协助中国企业及投资者拓展海外业务,进行科学、合理合规的国际化战略规划。

旗下中关村硅谷、波士顿创新中心,位于美国创新创业资源两处核心地带,设有孵化器、共享办公空间、私人办公室、活动中心等多种功能空间,每年主办 200 余场技术分析会、学术讲座及创投活动,即吸引当地前沿技术和团队入驻孵化,又作为中国企业对外交流及拓展市场的软着陆点 ,是推动当地中美科技创新交流及产业化发展的重要交流中心。
关于青年学者联盟YSA

青年学者联盟YSA(Young Scholars Association)致力于打造青年学者的学术/工业交流平台,为广大青年学生学者服务。YSA希望聚集有志之士,上下求索,探未来之路 。欢迎扫描二维码关注YSA公众号!

如果读者有加入YSA青年学者交流群,欢迎扫码添加 YSA小助手为微信好友,有问题继续交流。请注明:加入YSA交流群

綠葉製藥Rykindo®有望成為我國首個在美獲批上市的創新藥

作為國家“重大新藥創制”科技重大專項之一,備受關注的自主研發新藥——注射用利培酮緩釋微球Rykindo®LY03004)已於美國東部時間328日,正式向美國食品藥品監督管理局(“FDA”)提交NDA新藥上市申請,有望成為我國首個在美獲批上市的創新藥。

綠葉製藥此次申報Rykindo®被業界視為一大里程碑,意味著公司投入多年的長效緩釋製劑研發平臺成功突破產業化瓶頸。這不僅是綠葉製藥全球化戰略中的關鍵一步,也是中國在全球製劑創新舞臺上邁出的一大步,受到各界廣泛關注。通過製劑開發、CMC及工藝優化、產能放大,註冊審評、商業化籌備等層層考驗,綠葉製藥已為Rykindo®及後續多個創新製劑的全球上市做好充分準備。

Rykindo®是綠葉製藥自主研發的緩釋微球製劑,以肌肉注射的方式每兩周給藥一次,治療精神分裂症和雙向情感障礙。此次提交的NDA新藥申請包含了一項關鍵性及兩項支持性臨床試驗的結果,共涉及172名美國病患。該項關鍵研究顯示:與利培酮長效注射劑的市場參照產品相比,首次注射Rykindo®後並無滯後期,且具有相等穩態藥代動力學。在所有三項研究中,Rykindo®與參照產品的安全性基本相似;在療效上,Rykindo®首次注射後三周毋須再服用口服製劑,且能更快達到穩態血藥濃度。Rykindo®上市後,可改善口服抗精神病藥物在精神分裂症患者中普遍存在的用藥依從性,每兩周給藥一次,將簡化精神分裂症的療程。

綠葉製藥預計,Rykindo®有望於2019年至2020年在美國和中國先後上市。與此同時,該新藥在歐盟和其他新興國家或地區的註冊也在同步順利推進中。

Rykindo®所處的中樞神經用藥領域,全球患者人群異常龐大且不斷增加。綠葉製藥在該治療領域進行的一系列佈局,將成為其下一階段業務增長的關鍵發力點。目前,公司已上市的中樞神經藥物包括:思瑞康及其緩釋片、卡巴拉汀單日貼片、芬太尼貼片、丁丙諾啡貼片等,這些產品覆蓋全球80多個國家和地區,包括中國、美國、歐盟、日本等主要醫藥市場,以及快速增長的國際新興市場。後續在研產品線中,另有注射用羅替戈汀緩釋微球(LY03003)、鹽酸安舒法辛緩釋片(LY03005)、帕利呱酮緩釋混懸注射劑(LY03010)、卡巴拉汀多日貼片(LY30410)等中樞神經新藥已在中國和海外同步進行開發。公司期待將更多優質創新的原研藥品帶給全球患者

綠葉製藥集團管理層表示:我們將全力推進Rykindo®在美國和中國的上市,並加速多個已處於NDA準備階段、III期及關鍵臨床階段的新藥的註冊進度。我們期待綠葉製藥能把更多優質創新的原研藥品帶給有需要的全球患者!”

Dr. Mien-Chie Hung, the president of CMU, will be in Boston to recruit overseas talent. It is a great opportunity to learn about upcoming faculty job opportunities in Taiwan!

In addition to clicking "going", please fill out the registration form if you are interested in attending: https://goo.gl/forms/bUXKEx9tdXMTduK33
  • Friday at 6 PM – 8:30 PM
    3 days from now3948°F Cloudy
  • Room D1620, Dana-Farber Cancer Institute, 44 Binney Street, Boston
中國醫藥大學招聘說明會
Time: 6pm-8:30pm, April 5th, 2019
Location: Room D1620, Dana-Farber Cancer Institute, 44 Binney Street, Boston
Agenda:
6:00pm-7:00pm Registration and Reception dinner 報到 & 晚餐
7:00pm-8:00pm Recruitment talk by Dr. Mien-Chie Hung 中國醫藥大學洪明奇校長攬才演講
8:00pm-8:15pm Q&A
8:15pm-8:30pm Introductino of MOST programs for overseas talents 波士頓科技組謝水龍組長介紹海外人才歸國橋接方案



2019 Boston BioForum

CABA 















Boston BioForum
May 4, 2019
波士顿生物医药论坛| CABA
Driving Transformation in Life Sciences Industry
ABOUT
The goal of the annual conference is to invite prominent entrepreneurs, investors, biotech and pharma executives, academic and industry scientists, as well as professionals from the legal, finance, and health- care fields to talk about hot topics in the Life Science industry. 
- Future of Immuno-Oncology
- Outlook of Cell & Gene Therapy
- AI & Big Data in Health
- Evolving Landscape for Life Science Investment
- Next Big Thing in Biotech & Pharma
Time & Location
Saturday, May 4, 2019 @ 9AM EST
The Westin Waltham Boston
70 3rd Ave, Waltham, MA 02451


Confirmed Speakers
Will Brownsberger
 MA State Senator 


Jos Melenhorst    
Director, CAR-T Product Development
UPenn

Jonathan Terrett    
Head of Immuno-Oncology
CRISPR Therapeutics    

Sadik Kassim    
Executive Director
Kite Pharma    

Nenard Grmusa    
SVP, Head of External Innovation
Takeda    

Lei Xiao    
CEO
Innovative Cellular Therapeutics


Derrick Li    
Head of Strategy and Investor Relations
Cellular Biomedicine Group

Nick Valiante    
CEO
Glyde Bio    

F. Stephen Hodi    
Directot, Center for IO
Dana Farber Cancer Institute, Harvard Medical School

William Cao    
CEO
GraCel    

Rob Brainin    
CEO
NextCODE

Catherine Sabatos-Peyton  
Head of IO
Novartis    

Partial List of Sponsors from Past CABA Events 
CABA is a 501(C)(3) not-for-profit professional organization registered in Massachusetts since May 2007. CABA is committed to promote public awareness of advancement in the pharmaceutical and biomedical industry, professional interactions in the fields of life sciences, global biomedical innovations and business development.
Chinese-American BioMedical Association

2019 SAPA-NE职业发展研讨会: Jump-Start Your Career!

SAPA-NE 美中药协SAPA
你想知道如何在职业生涯的不同阶段做出选择吗















你想了解求职中签证移民的准备策略吗?
你知道如何从导师那里受益吗?
你想成为一个更好的沟通者吗?
你想知道如何管理你的老板吗?
你想提升自己的领导能力吗?
你想拓展建立自己的社交网络吗?
你想拥有一张职场头像照片吗?

欢迎加入我们2019 SAPA-NE职业发展研讨会: 
Jump-Start Your Career!
3月30日上午10:00  - 下午6:00
Tufts University, Robinson Hall Room 252, 212 College Ave, Medford, MA, 02155
寻求指导, 分享智慧, 建立职业生涯。
Speakers
K.C. Donovan
Executive Director, DonoVision

Yaran Pan, LLM
Attorney at Law Office of Yaran Pan

Huijuan Li, Ph.D.
Head of Analytical Development, Moderna Therapeutics

Chen Cui, Ph.D.
Associate, McKinsey & Company

Peng Meng Kou, Ph.D.
Commercial Development Manager, MicroMedicine

Sumiao Chen, M.D., M.S.
Pharmacologist, Novartis Institute for Biomedical Research
CEO of SUMIAO XIANG restaurant

Dominic Yee, J.D., Ph.D.
Corporate Counsel, Sunovion Pharmaceuticals

Michael H Zhao, Ph.D.
CEO, Longwood Biology Inc.

★ Program ★
文字编辑:李科杰,梁雪,郭佳  微信编辑:李源涛


















Registration Is Now Open for Biotech's Can't Miss Event: BIO 2019
In just 4 months, 16,000+ biotechnology and global pharma leaders will come together for an exciting week of intensive networking to discover new opportunities and promising partnerships. We bring together a wide spectrum of life science and application areas including drug discovery, biomanufacturing, genomics, biofuels, nanotechnology and cell therapy.

Join the global biotech community to discover the next generation of cutting-edge products, innovation, therapies, and cures at events all week long.


BTBA Special Talk: National Taiwan University AI Center
Saturday, December 1, 2018 at 10:00 AM – 12:00 PM EST
MIT Building E25; Room 119/121
BTBA Special Talk: We are the honor to invite Dr. George Tseng to give us an introduction of National Taiwan University (NTU) - Artifical Intelligence (AI) Innovation Research Center. This NTU-AI center was founded in 2018 and under Taiwan's Ministry of Science and Technology (MOST; 科技部). The Center is composed of two sub-centers: 1). Artificial Intelligence Technology sub-center and 2). All Vista Healthcare sub-center. Please come to join us for enjoying this BTBA special talk to know the Technology development in Taiwan! 

BTBA 特別演講:這次我們邀請到台大人工智慧中心 (NTU-AI Center) 的曾柏元 副執行長,來跟大家介紹科技部在2018成立的台大人工智慧中心!此中心的全名為人工智慧技術暨全幅健康照護聯合研究中心,簡稱台大人工智慧中心或台大AI中心,包括智慧技術和生技醫療兩個主題、人工智慧技術及全幅健康照護兩個子中心。歡迎大家一起來聆聽並了解一下台灣目前的科技發展


著名的中医专家张季教授、中医科研专家李秀敏教授、中药颗粒剂专家天江药业总裁俞敏及Eric Brand博士将于11/11/2018莅临2018 哈佛中医药论坛暨天江中药配方颗粒学术论坛讲课。此次论坛将授予九个学分,收费(包括午餐)会员仅$60、非会员$90,哈佛Faculty, Fellow, Students 免费(需出示哈佛ID), 


ISCT publishes annual report on cell and gene therapy market authorisations

Report to enable patients and entire cell therapy community to identify treatments approved by government regulatory authorities

Vancouver, Canada, November 20, 2018 – ISCT, the International Society for Cell and Gene Therapy, the global professional society of clinicians, researchers, regulatory specialists, technologists and industry partners in the cell and gene therapy sector, today announces the first publication of its new annual report detailing global cell and gene therapies (CGT) with market authorization.

The CGT market authorization report is intended to provide a centralized resource and increased clarity for all of those involved in the CGT industry. This involves the scientific community, healthcare stakeholders and patient associations. The report will be a regularly updated document that will be republished yearly, and accessible through the ISCT website, www.celltherapysociety.org, and www.isct-unprovencellulartherapies.org.  

The report has been designed to react to the increase in momentum around a widening number of CGT authorizations, as well as a parallel increase of unproven approaches where cells are delivered as treatments without rigorous scientific and regulatory assessment and authorization. 

The report has been prepared by select members of the ISCT Presidential Task Force (PTF) on the Use of Unproven and/or Unethical Cell & Gene Therapies (UCGT) with lead authors Natividad Cuende (Executive Director, Andalusian Initiative for Advanced Therapies, Seville, Spain) and Laertis Ikonomou (Assistant Professor of Medicine, Boston University School of Medicine, Boston, MA). The ISCT Presidential Task Force was formed in 2014 to support ISCT’s ongoing commitment to address the rise of commercially available unproven or insufficiently proven CGT treatments. These approaches are targeted at hopeful individuals seeking cures or health improvement for a variety of conditions. The PTF-UCGT characterizes unproven cellular interventions and promotes safe and effective practices worldwide. 

The reliable, up-to-date resource will help patients to make informed decisions before receiving a CGT treatment so that they can avoid being exposed to unproven and unlicensed cell interventions not approved by a regulatory or medicine agency.

The report also provides an annual breakdown of CGTs that have received, as well in some cases, have withdrawn, market approval. This includes analysis on types of product and therapy as well as disease targeted. 44 unique products were identified. 84% were cell and tissue therapies, and 55% were autologous. More than one third target oncological or hematologic conditions. 

In the US, there are over 16 cell, tissue and gene products with marketing authorization, 14 in Korea, eight in Europe, four in India and Japan, two in Canada, and one each in China and Australia. This contrasts with Russia, Middle East, Africa, Central and South America, which have no CGT market authorizations or data available. 

“The number of market approved cell and gene therapy treatments continues to grow, with a high number of other therapies seeking approval. It is critical for all those involved in the sector, and most importantly those patients that may benefit from newly approved treatments, to have an annually updated resource detailing all approved cell and gene therapies,” said Massimo Dominici, Chair of the ISCT Presidential Task Force on Unproven and Unethical Cell & Gene Therapies. “This resource will give patients visibility on what cell and gene therapies have gone through proper approval processes, and help them alongside physicians to make more informed decisions about their treatment.”


In tandem with the efforts of professional societies like ISCT, it is imperative that the regulatory environment and guidance keep pace with the rapid advancements in cell and gene therapy. As such, this report also supports ISCT the FDA’s continued publication of numerous draft CGT guidance documents in 2018.

2018 Harvard TCM & Tianjiang Granule Extracts Forum
Time: 8:45am-6:00pm Sunday November 11, 2018
Place: Harvard Medical School, McLean Hospital, 115 Mill Street, Belmont,
MA 02478
Parking: Free
CEUs (Continue Education Credit): 9 credits
Fee (lunch included): Members $60, none members $90
Free for Dr. Lee’s group, Harvard Faculty/Fellow (NO CEU, reservation
needed)
Sponsored: Massachusetts Society of Chinese Medicine (MSCM)
Alternative Medicine Center, McLean Hospital, HMS
Supported: Tianjiang Pharmaceuticals. CO.
Program
8:45-9:15am Registration
9:15-11:30am 七方理論臨床運用心得 张季
Experience in Clinical Application of Seven Formulas Theory dr.
Ji Zhang PhD, L.Ac
11:30-12:10pm Traditional Chinese Medicine, Western Science, and the Search
for a Cure for Allergies
Prof. Xiumin Li, MD New York Medical College
12:10-12:50pm 天江中药配方颗粒研究进展 俞敏 天江药业总经理
Progress on Tianiiang Granule Extracts Research Min Yu, CEO of Tiangjiang
Pharmaceuticals. Co.
12:50-2:10pm Lunch & discussion

2018 哈佛醫學院中醫藥論壇
暨天江中药配方颗粒学术论坛
2:10pm-2:40pm 配方颗粒的国际趋势:标准与临床特点 Eric Bran PhD
Global Trends in Granule Extracts: Standards and Clinical Styles Eric Bran
2:40-5:40pm 升陽益氣諸方劑在脾胃病的應用體會
Application Experience of Yang-raising and Qi-augmenting Formulas in
Spleen-Stomach Diseases Dr. Ji Zhang, PhD, L.Ac
5:40-6:00pm Discussion
Contact
Call Dr. Li 617 323 7809 or
Email:Johnzhang999@gmail.com
张季哈佛中医论坛講座簡介
1. 七方理論臨床運用心得
“七方“學說始見於《內經》。七方,即指大方、小方、緩方、急方、奇方,偶方、複方。歷代
醫家如金代張元素《醫學啟源》、張子和《儒門事親》、成無己《傷寒明理論》、明代李時珍《
本草綱目》均有闡發補充。國內各版高等中醫院校教材《方劑學》均認為“七方”為最早的方劑
分類法,臨床醫師多因其簡約古老而棄之不用;查閱中醫藥文獻,亦鮮見有關七方的理論與臨床
研究論文。而張季中醫師在臨床中體會到“七方“是指導臨床組方的利器,是提高臨床療效的法
寶,多年來鍥而不捨地研究“七方“理論的臨床應用,頗有心得。此次講座將結合臨床多個成功
案例分別加以詳細闡述。
2. 升陽益氣諸方劑在脾胃病的應用體會
胃腸道疾病在美國社會常見,與飲食不調和過重的精神壓力有密切關係,也有因長期使用西藥的
副作用而引發或加重。脾胃病為中醫之擅長。其治則不外疏肝解鬱,理氣止痛,益氣健脾,化濕
助運,活血化瘀,溫腎暖脾等等。但是對於一些疑難病症的治療,療效亦不甚滿意,張季中醫師
在脾胃病治療方面,宗金元易水學派張元素、李東垣等醫家的學說,在臨床中以臟腑標本虛實用
藥和升陽益氣、升陽除濕、升陽散火、升陽瀉濁法相結合,有一些體會,這次講座並將提供一些
治療成功的案例。
講員履历
張季,1978 年入學南京中醫藥大學中醫系,1983 年畢業後旋即留校任教,曾師從各家學說大家丁
光迪先生研究《諸病源候論》,碩士研究生期間又師從蜚聲海內外的《中醫學概論》、《中藥大
辭典》的主編吳貽谷導師,專攻中藥方劑的臨床應用,曾參加編寫《中華本草》《現代中藥學大
辭典》等10 餘部學術著作,其中多部獲獎。1992 年來美,又在美國獲DAOM 博士學位。張季中
醫師至今已在中美兩地臨床35 年,應用中藥方劑辨證施治,經驗豐富,對脾胃病、肝膽病、婦科
病、皮膚病的治療,特別是對過敏性疾病、感染性疾病和自身免疫性疾病的治療,頗有心得。自
1995 年起,先後執教於洛杉磯多家中醫院校碩士班和博士班。近年來,多次在美國各地中醫公會
講授再教育學分課程,並返回母校作多次學術演講,廣受好評。張季中醫師目前为世中聯內科專
業委員會理事、世中聯中醫藥推廣海外專家委員會委員、世中聯中藥上市後安全性再評估美國專
家委員會委員;并任南京中醫藥大學客座教授,南京中醫藥大學美洲校友會副會長,江蘇省中醫
院洛杉磯惠僑中心顧問。
俞敏,男,1973 年6 月出生,长江商学院EMBA 硕士,高级经济师,江苏省中药饮片研究专委会
常委副主委,现任江阴天江药业有限公司总经理。江阴天江药业有限公司成立于1992 年,隶属于
中国医药集团旗下中国中药控股有限公司。背靠中国医药集团这家中国规模最大、产业链最全、
综合实力最强的超千亿医药健康产业集团,天江药业及其中药配方颗粒产品致力于传承创新,以
优质中药产品和服务提升人民健康水平。天江药业是国内首家“全国中药饮片改革试点单位”,
首批“中药配方颗粒试点单位”,是中药配方颗粒行业的先驱者和领跑者。
俞总将详细介绍天江中药配方颗粒质量控制措施与机制,以及天江中药业配方颗粒生产工艺流程
Xiu-Min Li, M.D., M.S.. Dr. Li obtained her MD degree in Henan University
of Chinese Medicine (Zhengzhou) in 1983 and a Master’s degree in Clinical
Pediatric Immunology from The Graduate School of China Academy of
Chinese Medical Sciences (Beijing). She was a Visiting Scientist at Stanford,
and postdoctoral fellow in Clinical Immunology at Johns Hopkins (Baltimore)
where she was appointed instructor in 1997. She Joined the Division of
Pediatric Allergy and Immunology, Pediatric Department and was promoted
to Professor of Pediatrics with tenure at the Icahn School of Medicine at
Mount Sinai in 2009. She has combined expertise in immunology and
Chinese medicine. Her research has yield over 100 publications. She has trained over fifty
residents, clinical fellows, post-doctoral fellows, graduate students, medical students, and
visiting scientists. She has chaired prominent committees about the use of alternative medicines
for allergic diseases in the US and internationally. She recently joined Department of
Microbiology and Immunology as Professor and in the process to establish a Center of
Excellence for Clinical Immunology and Integrative Medicine. She was awarded the Future of
Health Technology Award for 2016. She is co-author of Traditional Chinese Medicine, Western
Science, and the Search for a Cure for food allergy with Henry Ehrlich.
Eric Brand is a licensed Chinese medicine practitioner with a passion for materia medica and
herbal quality discernment. After graduating from the Pacific College of Oriental Medicine in
2003, Eric spent over a decade pursuing academic and clinical opportunities in Taiwan, Hong
Kong, and mainland China. He earned his PhD at the School of Chinese Medicine at Hong
Kong Baptist University with a focus on Chinese herbal pharmacy, and he serves as a TCM
advisor to the American Herbal Pharmacopoeia. Eric has written or translated a variety of
modern and classical texts and peer-reviewed articles, and he served as Chair of the U.S.
delegation on the ISO Technical Committee for international TCM standards (ISO TC 249) from
2014 to 2017.

Welcome to the “1st International Conference on the Forefront of Complementary and Integrative Medicine,” which takes place at the Joseph B. Martin Conference Center of Harvard Medical School in Boston October 29-30, 2018. Please visit the website for more details: https://www.icfcim.com

2018年10月29-30日,哈佛大学医学院Josheph B Martin Conference Center  首届中西医替代及整合医学大会  最后一周注册机会!大会由哈佛医学院和北京中医药大学主办 Journal of  Phytomedicine ,麻州中医学会协办,届时世界顶级专家教授云集,包括哈佛医学院、NIH、斯坦福大学等十位著名教授李豫伟Thomas Efferth、北中医徐安龙校长,哈佛医学院结合医学系主任,NIH补充结合医学中心主任Helene Langevin,香港浸会大学中医学院院长吕爱平,香港中文大学中医药研究所所长梁秉中,北中医东方医院副院长林谦等。聆听中西医学发展前沿,领略名家风采,机会难得!对哈佛和MIT学生、Speaker 团队成员免注册费,提供会议午餐,但免费名额有限(签到时需提供学生或工作ID),请参会人员尽快注册https://www.icfcim.com/registration.html。




Saturday, September 8th
1:00 - 5:00 p.m. (EST)
Harvard School of Public Health 
Kresge G1
On-Site Judging Teams
Jessica Alderman Zeaske, Ph.D., MBA
Director, Healthcare Investments, GE Ventures
SU Lingyun
Director, Alibaba Health Research Institute
SHAO Qing
Senior VP at Porton;
Founder and Director, Beijing Bodun Chongde Charity Investments; Founder and Director of Network Think Tank;
Vice President, Moganshan Research Institute Expert Advisory Committee;
Vice Chairman, China Digital Assets Research Institute;
Director, United States Hope Investment Fund
Jing Ma, MD, PhD
Co-founder and Board Member, President, U.S.-China Health Summit; Director of China Center,
Associate Professor, Department of Population Medicine, Harvard Medical School
Kate (Xiaokui) Zhang
Senior Director, Global Bio-Therapeutic, Sanofi 
Shaan Gandhi, MD, MBA
Principal , Longwood Fund
Olivia Ho. Cheng
Board Member, U.S.-China Health Summit; CEO, Aurora Healthcare Corp.
Grannum R Sant, MD, FRCS, FACS
Professor and Former Chair of Urology and Urology Residency Program Director, Tufts University School of Medicine
ZHANG Rui
Partner, Lodestone Capital Partners
YANG Hailing
Senior Analyst, Decision Resources Group
Register to connect with judge panel right now!
More information? please visit: https://www.uschinahealthsummit.org/innovation
Any questions? Reach us at info@uschinahealthsummit.org
各位会员:好消息。著名医学气功专家北京中医药大学博导刘天君教授将于9/30/2018周日莅临哈佛中医药论坛授课!本次讲课包括现场带领大家练习。名额有限,先来先得。欢迎大家参加!请提前报名!谢谢!John Zhang
药明生物宣布投资6000万美元在美国新建生产基地

药明生物国际化战略再下一城
首次在美国布局生物制药生产基地

美国马萨诸塞州伍斯特市,中国上海,2018611——全球领先的开放式生物技术平台公司药明生物(WuXi Biologics, 2269.HK)今日宣布,公司计划投资6,000万美元(约合3.8亿人民币)在美国马萨诸塞州伍斯特市(隶属波士顿大都会区)新建现代化生物制药临床样品和商业化生产基地,并创造约150个工作岗位。

这是药明生物在全球范围布局的第十一个生产基地(药明生物十一厂),也是药明生物首次在美国新建生产基地,同时也是公司继爱尔兰、新加坡后投资建设的第三个海外生产基地。

药明生物为全球生物制药公司和生物技术公司提供全方位的端到端研发服务,其使命是加快和转变生物制药发现、开发及生产,造福全球患者。

即将开建的药明生物美国基地将继续采用全球领先的一次性生物反应器,并率先应用“新一代生物制药生产技术”(连续生产工艺)开展商业化生产,致力于成为全球领先的生物制药“未来工厂”。该基地总产能将达到4,500升,包括22,000升流加细胞培养反应器与1500升灌流工艺生物反应器,基地建成后将拥有生物工艺开发实验室,并同时具备临床样品生产和小规模商业化生产的能力。此项目的推进得到了马萨诸塞州政府、伍斯特商业发展局(WBDC)和麻省生命科学中心(MLSC)的大力支持。

“马萨诸塞州拥有技术领先的公司、顶尖的学术机构和充满竞争力的人才,已经形成全球最具活力的生命科学创新生态系统之一。”马萨诸塞州州长查理·贝克(Charlie Baker)先生说,“我们很高兴药明生物选择在马萨诸塞州进行战略布局,更多企业的投资和快速发展将共同构建更加完整的创新生态系统。”

“这几天在伍斯特市与药明生物管理层的会见交流,让我深信他们将对这里的生命科学产业做出巨大贡献。”马萨诸塞州副州长卡琳·波利托(Karyn Polito)女士表示,“我们很高兴为伍斯特市生物医药产业园的发展而努力,我们将继续为各个领域的合作伙伴提供支持。”

“伍斯特市正在打造全新的生物医药产业园区,我们热烈欢迎药明生物成为首家选择入驻于此的企业。”伍斯特市政执政官Edward M. Augustus, Jr.先生表示,“作为全球生物医药市场中地位日益攀升的投资目的地,伍斯特市十分期待新园区的正式开幕,同时帮助药明生物的首个美国生产基地顺利落成。”

“我们很高兴药明生物选择了美国马萨诸塞州,更重要的是选择了伍斯特市。在马萨诸塞州贝克-波利托政府和伍斯特市政府的支持下,我们通过巨大努力最终促成了此项目成功落地。对伍斯特市而言,今天又是一个重要的日子。”伍斯特商业发展局总裁兼首席执行官Craig L. Blais先生表示。

麻省生命科学中心(MLSC)总裁兼首席执行官特拉维斯·麦克瑞迪(Travis McCready)先生表示,“我们很高兴见证药明生物在美国伍斯特市布局生产基地这一重大里程碑。药明生物全球领先的生物制药专业技术和能力将进一步巩固这里的生命科学创新生态系统,帮助马萨诸塞州的生物制药公司更迅速高效地开发创新疗法。我们将继续为此项目的顺利完成而努力。”

“波士顿大都会区是公认的世界生命科学领域的创新聚集地,药明生物的美国新基地在公司国际化战略中具有至关重要的作用,有助于确保公司生产的符合最高质量标准生物药,通过健全强大的供应链网络,造福全球患者。非常感谢美国马萨诸塞州各界人士对我们的大力支持,相信在大家共同的努力下,这个振奋人心的项目将迅速得到推进。”药明生物董事长李革博士表示。

药明生物首席执行官陈智胜博士表示:“我们非常高兴能在美国伍斯特市投建公司在美国的第一个生产基地,公司众多重要合作伙伴距离此基地车程仅2小时。新基地将有助于满足药明生物日益增长的生物制药开发及生产需求,从而更好地帮助当地合作伙伴加速生物药开发进程。药明生物致力于打造全球生物制药领域更宽、更广、更深的生物制药能力和技术平台,赋能当地及全球合作伙伴。”
关于药明生物
药明生物作为一家香港上市公司,是全球领先的开放式、一体化生物制药能力和技术赋能平台。公司为全球生物制药公司和生物技术公司提供全方位的端到端研发服务,帮助任何人、任何公司发现、开发及生产生物药,实现从概念到商业化生产的全过程,加速全球生物药研发进程,降低研发成本,造福病患。如需更多信息,请访问:www.wuxibiologics.com.cn

WUXI BIOLOGICS TO INVEST $60 MILLION TO ESTABLISH A BIOLOGICS PRODUCTION FACILITY IN THE UNITED STATES

WuXi Biologics to Invest $60 Million to Establish a Biologics Production Facility in the United States
– WuXi Biologics’ first overseas site in the United States
2018/06/11
WORCESTER, MA and SHANGHAI, June 11, 2018 – WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announced that it is to invest $60 million and hire approximately 150 employees to establish a state-of-the-art biologics clinical and commercial manufacturing facility in Worcester, Massachusetts in the United States. The facility will be WuXi Biologics’ 11th global drug substance manufacturing facility (MFG11).
WuXi Biologics is a leading global platform company providing end-to-end solutions for biologics with a mission to accelerate and transform biologics discovery, development and manufacturing to benefit patients around the world.
This state-of-the-art “facility of the future” will be built upon the novel approach that WuXi Biologics has pioneered in deploying single-use bioreactors. It is also designed to run continuous bioprocessing, a next-generation manufacturing technology to be implemented in America for the first time. A total of approximately 4,500 L bioreactor capacity will be installed with two 2,000 L traditional fed-batch and one 500 L perfusion-based continuous processing. This facility will handle both clinical and small volume commercial production. An early-stage bioprocess development lab will also be included.
The new manufacturing facility supported by the Government of Massachusetts, the Worcester Business Development Corporation (WBDC) and the Massachusetts Life Sciences Center (MLSC), is the Company’s first overseas site in the United States, as well as the third outside China subsequent to Ireland and Singapore new sites.
“Massachusetts is home to one of the world’s most dynamic life sciences ecosystems, with leading companies, top-tier academic institutions, and a globally-competitive workforce,” said Massachusetts Governor Charlie Baker. “We are enriched when companies grow and invest here and are pleased to welcome WuXi Biologics’ expansion.”
“Having met WuXi Biologics’ leaders during their recent trip to Worcester, I am confident that they will contribute greatly to the city’s life sciences industry,” said Ms. Karyn Polito, Lieutenant Governor of Massachusetts. “I have been pleased to work on the development of Worcester Biomanufacturing Park and our Administration remains committed to supporting our public private partnership.”
“The City of Worcester is thrilled to welcome WuXi Biologics as its first tenant to the new Biomanufacturing Park,” said Worcester City Manager, Edward M. Augustus Jr.. “As a growing destination in the global biomedical market, the city looks forward to officially opening this impressive campus and is eager to host WuXi Biologics in their first US manufacturing facility.”
“We are delighted that WuXi Biologics has chosen the United States, Massachusetts, but most importantly Worcester. We competed very hard for this one and we prevailed. The Baker / Polito Administration and the City of Worcester stepped up to make this possible. Another great day for Worcester,” said Mr. Craig L. Blais, President and CEO of WBDC.
“We are excited to reach this important milestone on developing WuXi Biologics’ first US bio-manufacturing facility and to announce their intention to move to Worcester,” said Mr. Travis McCready, President and CEO of MLSC. “WuXi Biologics brings a global biologics manufacturing expertise that will enhance our life sciences ecosystem and help Massachusetts biopharma companies develop novel therapies quickly and efficiently. We look forward to continuing to work to finalize this project.”
“Metropolitan Boston is acknowledged as a leader in the biopharmaceutical industry. The new site plays a key role in WuXi Biologics’ global bio-manufacturing network to ensure that biologics are manufactured at the highest quality and within a robust supply chain to benefit patients worldwide. We are grateful for all the support local agencies and the talented people here have provided for us. We believe we can quickly push forward this exciting project,” said Dr. Ge Li, Chairman of WuXi Biologics.
Dr. Chris Chen, CEO of WuXi Biologics, added, “The new site will undoubtedly meet WuXi Biologics’ growing need for biologics development and manufacturing in the near future. Many partners of WuXi Biologics are located within two hours of this new site. We are all very excited to initiate our first US site to enable local companies and expedite biologics development in the United States. We are committed to becoming the most comprehensive capability and technology platform in the global biologics industry to enable both local and global partners.”
About WuXi Biologics
WuXi Biologics, a Hong Kong-listed company, is the only open-access biologics technology platform in the world offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing. Our company history and achievements demonstrate our commitment to providing a truly ONE-stop service offering and value proposition to our global clients. For more information on WuXi Biologics, please visit www.wuxibiologics.com.















20th SAPA-NE Annual Conference, Cambridge, MA, 

Jun 2-3

















Please Join Us to Discuss 
How Can We Save the Lives of
Patients, Our Family Members,
Our Neighbors, and Ourselves.

 
Overview
June 2nd
8AM – 6PM
Annual Conference
Tang Center, MIT
June 2nd
6PM – 9:30PM
20th-Anniversary Banquet
Boston Marriott Cambridge
June 3rd
9AM - 3 PM
Investment Forum
Boston Marriott Cambridge

 
Agenda
Helping Patients with Unmet Needs Through Innovation and Collaboration
June 2nd, 2018
8:00 AM – 6:00 PM
MIT, E51, Tang Center, Wong Auditorium
2 Amherst St, Cambridge, MA
8:00–9:00
Registration and Breakfast
9:00–11:55
Session 1: 
Patients with Unmet Needs Require New Treatment and Healthcare Innovation
11:55–13:00
Lunch and Exhibition
13:00–14:20
Session 2: 
Transformative Innovation Demands Novel Platforms
14:20–15:00
Coffee Break and Exhibition
15:00–16:40
Panel Forum:
Collaborations and Opportunities Across the Ocean
16:40–17:40
Session 3: 
Global Collaboration Drives Biomedical Innovation and Productivity
17:40–18:00
Closing Remark and Networking


SAPA-NE 20th Anniversary Celebration Banquet
(Biocytogen Night)
6:30 PM – 9:30 PM
Boston Marriott Cambridge
50 Broadway, Cambridge, MA
18:00–18:30
Networking
18:30–18:35
Welcome Remarks
18:35–19:10
Keynote Speech and Award
19:10–21:30
Dinner / Celebration


Biotech/HealthCare
Investment Forum
June 3rd, 2018
9:00 AM – 3:00 PM
Boston Marriott Cambridge
50 Broadway, Cambridge, MA
9:30–9:40
Opening Remark
9:40–11:20
Keynote Talks
11:20–12:00
Panel Discussion
12:00–13:00
Lunch
13:00–14:30
Roadshow Presentation
14:30–15:00
Conclusion


 
Invited Speakers
George M. Church, Ph.D.
Professor 
at Harvard & MIT
Dost Öngür, M.D.
Chief of the Psychotic Disorders Division, McLean Hospital
Shidong Jia, Ph.D.
Founder & CEO, Predicine Holdings Ltd.
Chris Garabedian
Chairman and CEO, Xontogeny
WilliamL. Fodor, Ph.D.
Acting CSO Biostage, Inc. 
Director Translational Sciences, Cell Therapy Group
Morris J. Birnbaum, M.D., Ph.D. 
SVP and CSO, Internal Medicine Research, Pfizer Inc.
Steve Yang, Ph.D.
EVP, CBO & CSO, WuXi AppTec
Yuelei Shen, Ph.D.
President and CEO,  Biocytogen Co Ltd.
Shenghong Steve Yang, Ph.D.
Manager, Sales and BD at Sino Biological US Inc.
Hong Cheng, Ph.D. & MBA  
Associate Vice President, Head of Research Strategy and Effectiveness for Global Research at Sanofi
Jin Li, Ph.D.
Chairman and CEO, HitGen
Yulian Zhang, Ph.D., MBA 
Executive Director, Kelun-Biotech Pharmaceuticals
Bill Liang, Ph.D.
CEO, CF PharmTech, Inc.
史文钊, Ph.D.
神州医疗科技股份有限公司总裁
Libing Yu, Ph.D.
Sr. Vice President, Business Development, Viva Biotech
Wenseng Wendy Pan, J.D. & Ph.D.
Partner, Sidley Austin LLP.

Ken Li, Ph.D.
Managing Partner, Yuanming Capital
Scott Zheng, MBA
Partner & CEO, SunForest Captital
Brad Loncar
CEO, Loncar Investments

 
Partners




You are warmly welcome to join our "20th SAPA-NE Annual Conference and 20th Anniversary Celebration" at MIT/Marriott Cambridge on Sat-Sun 6/2-6/3/2018 (www.SAPA-NEweb.org) 
The theme of 20th SAPA-NE Annual Conference (Sino-American Pharmaceutical Professionals Association - New England)  is “Helping Patients with Unmet Needs through Innovation and Collaboration”. Please join us to learn and to discuss this important topic in our lives with Big Pharmaceutical Executives, Star-up Biotech Entrepreneurs, Well-known University Professors, Famous Physicians, and International Investors. We are confident that you would not only learn frontier science, grasp the latest Drug R&D trend, understand updated medical advancement, but also find the conference as a unique opportunity expand your professional network in particular with pharmaceutical/biotech and Health Care industry with Chinese origin. Hope everyone also enjoy the memorable SAPA-NE 20th Anniversary.
The Annual Conference comprises a full-day program on 6/2 Sat 9am-6pm at MIT Tang Center, Wong Auditorium at 2 Amherst St, Cambridge, MA, followed by a SAPA-NE 20th Anniversary Banquet 6:30-9:30pm at Boston Marriott Cambridge, 50 Broadway, Cambridge, MA. In addition, we will have a Biotech/HealthCare Investment Event and Special Activities at Boston Marriott Cambridge on 6/3/2018 Sunday 9am-3pm.
欢迎来波士顿参加20届新英格兰美中药协年会和20周年庆典, MIT and Marriott Cambridge, 6/2-6/3/2018. 制药公司总监,生物制药创业家, 知名学术权威,著名医学专家, 和投资巨鳄和大家一起探讨<通过创新和合作来帮助危难中的病人><Helping Patients with Unmet Needs through Innovation and Collaboration>
Registration at http://sapa-neweb.org/AC2018.php
Annual Conf Admission for both 6/2 9am-6pm and 6/3 9am-3pm, 
$25 early bird by 5/10; $30 regular by 5/25; $40 on site after 5/26
SAPA-NE 20th Anniversary Banquet, 6/2 6:30-9:30pm
$50 with limited capacity by 5/25; $60 on site after 5/26

Best regards,
20th SAPA-NE Annual Conference Organizing Committee
www.SAPA-NEweb.org

Taiwan Bio Forum: Healthcare Innovation Beyond Borders
Date:  Sunday, June 3rd
Venue:  Joseph B. Martin Conference Center (Harvard Medical School) 
In the advent of the International BIO Convention in Boston, join us for a day of healthcare and biomedical innovations at Taiwan Bio Forum, jointly hosted by MJNE and DCB on June 3rd at the Joseph B. Martin Conference Center at Harvard Medical School. Meet and network with top leaders in biopharma, medtech, venture capital, and academia from Taiwan and around the world.
This event will feature more than 20 speakers from Sanofi Genzyme, Samsung VenturesLEO PharmaSR One, M Ventures, MPM CapitalF-Prime CapitalArtiman VenturesMIT Alumni AngelsMilitia Hill Ventures, and Johnson & Johnson Innovation. The audience will also hear from keynote speakers Michael LaRhette, President, MassChallenge and Kate Merton, Head of JLABS at NYC & Boston, Johnson & Johnson Innovation.
Click photos for Speaker’s Bio
https://www.mj-ne.org/wp-content/uploads/2018/04/Trans_Herbert_Wu.png
Herbert Wu
President
DCB
https://www.mj-ne.org/wp-content/uploads/2018/04/Trains_Fong-Chin-Su.png
Fong-Chin Su
Deputy Minister
Ministry of Science and Technology
https://www.mj-ne.org/wp-content/uploads/2018/05/Mike_LaRette-300x300.png
Michael LaRhette
President
MassChallenge
https://www.mj-ne.org/wp-content/uploads/2018/05/Shen_Chen-Yang.png
Chen-Yang Shen
Chief Executive
Taiwan Biobank
https://www.mj-ne.org/wp-content/uploads/2018/05/David_Lucchino.png
David Lucchino
Chairman
MassBio
https://www.mj-ne.org/wp-content/uploads/2018/05/Trans_Johnsee-Lee.png
Johnsee Lee
Chairman
Taiwan Biotech Industry Organization
https://www.mj-ne.org/wp-content/uploads/2018/05/Shaoyu_Chang.png
Shaoyu Chang
Investment Manager
VI Ventures
https://www.mj-ne.org/wp-content/uploads/2018/04/Trans_k_merton.png
Kate Merton
Head of JLABS
Johnson & Johnson Innovation
https://www.mj-ne.org/wp-content/uploads/2018/05/Ko_Fulung.png
Fulung Ko
Chief Administrative Officer
Taipei Exchange
https://www.mj-ne.org/wp-content/uploads/2018/04/Joan-L-1024x548-300x300.png
Joan Lau
Managing Partner
Militia Hill Ventures
https://www.mj-ne.org/wp-content/uploads/2018/04/Trans_akhil-saklecha.png
Akhil Saklecha
General Partner
Artiman Ventures
https://www.mj-ne.org/wp-content/uploads/2018/04/Trans_Greg-new-large.png
Greg Sieczkiewicz
Chief IP Counsel
MPM Capital
https://www.mj-ne.org/wp-content/uploads/2018/04/Trans_Kevin-Chu.png
Kevin Chu
Analyst
F-Prime Capital
https://www.mj-ne.org/wp-content/uploads/2018/05/Christopher_Kim.png
Christopher Kim
Managing Partner
Novatio Ventures
https://www.mj-ne.org/wp-content/uploads/2018/04/Trans_Patrick.png
Patrick DeCourcy
Principal Program Manager
Sanofi Genzyme
https://www.mj-ne.org/wp-content/uploads/2018/04/Trans_Vikas.png
Vikas Goyal
Associate
SR One
https://www.mj-ne.org/wp-content/uploads/2018/04/Trans_Hyuk-Jeen-Suh.png
Hyuk-Jeen Suh
Head of Investment
Samsung Ventures
https://www.mj-ne.org/wp-content/uploads/2018/04/Trans_Michael_s.png
Michael Sierra
Vice President
LEO Sci. & Tech
https://www.mj-ne.org/wp-content/uploads/2018/05/Daniel_Franke.png
Daniel Franke
Analyst
M Ventures
https://www.mj-ne.org/wp-content/uploads/2018/05/Jeng-Hsin-1.png
Jeng-Shin Lee
Chief Scientific Officer
AB Biosciences
https://www.mj-ne.org/wp-content/uploads/2018/04/Trans_Marry_Ann.png
Mary Ann Picard
Dir. of Operation
M2D2
https://www.mj-ne.org/wp-content/uploads/2018/05/Patrick_Rivelli.png
Patrick Rivelli
President
Savran Technologies
https://www.mj-ne.org/wp-content/uploads/2018/05/Trans_YingTam.png
Ying K. Tam
Managing Dir. of Health
MaRS Ventures
https://www.mj-ne.org/wp-content/uploads/2018/05/Joel_Berniac.png
Joel Berniac
CEO and Co-Founder
Akrivis Technologies
Technology Showcase:
Company Name
Brief Company Introduction
Speaker
ACT Genomics
​ACT Genomics is a leading CAP-accredited cancer molecular information service provider, with proprietary NGS-panels and chip-based platform, coupling with integrated medical informatics pipeline, we transform cancer treatment paradigm and support biopharma in biomarker exploration and companion diagnostic development.
Tsung-Kai Wu
Sr. Associate Director, Business Development
Mao Ying Genetech Inc. ​
Mao Ying Genetech Inc. is a bioinformatics data analytic company dedicated to providing algorithmic technologies for diagnosis and therapy of cancer.  At Mao Ying, a multi-disciplinary team – comprising medical and computer scientists as well as a marketing expert – works together to develop diagnostic biomarkers for various types of cancer.  By applying the novel Gene Expression Portrait, we have successfully identified gene markers with potential applications to diagnosis or therapy, and developed several clinically validated products in this line, including OncoDx and MetaDx for cancer diagnosis and OrganID for human organ identification.
Pei-Ing Hwang​
General Manager
ASUS Life Corporation
ASUS Life focus on the development of smart medical application. With HealthCloud and AI application as the infrastructure, ASUS Life has PhenoFinder as a distributed database for medical data, OmniCare as a medical IoT platform, and AiNurse as a virtual application in telecare, to help hospitals develop the precision medicine.
Jerry Hsu
Senior Manager
Our mission is to create patient’s virtual avatar for better visualization to serve clinical and educational needs. Through Virtual Reality, our applications allow doctors to see through patient’s body for better surgical planning or radiotherapy simulation. In the student or patient education, the interactive and immersive learning experience enables users to eliminate conceptual hurdle so they can better understand human body. In Augmented Intelligence, our goal is to advance medical intelligence through simulated visualization.
Sam Jang
CEO
Funique VR
​Funique dedicated into realizing Stereoscopic 3D VR in film industry, and creating new generation platform for viewers.
Our Medical Stereo VR System - Observing Surgeries through Stereo VR Documenting all kinds of surgeries with Funique’s 8K per eye VR solution. Combining simulation and real-time footages, it solve the problems of lack of resources. And let medical students around the world have the chance to observe some of the greatest surgeons on earth.
Chien-Hsiang Chao
Project Manager
Bio Preventive Medicine Corp.
Bio Preventive Medicine Corporation (BPM) is a clinical-staged biotech company, focusing on developing novel biomarker-based diagnostics for chronic diseases and oncology. Our first product, DNlite, is a non-invasive urinary test for predicting/monitoring the progression of Diabetic Kidney Disease (DKD), which has been applied to evaluate renal effect in a phase IIIb global clinical trial, MARLINA-T2D™, sponsored by Boehringer Ingelheim. We can help in the development of drugs not only in evaluating renal efficacy but also renal safety. BPM welcomes strategic partnerships in expanding the product pipeline and technology platform for biomarker detection, as well as international partnership for commercialization.
Dave Lee
Scientist
LumiSTAR Biotechnology, Inc.
LumiSTAR Biotechnology is an expert in iPSC technology, optogenetic tools and functional indicators. There are two main applications of our technique: (1) All-optical platform incorporated with AI and machine learning for phenotypic screening, drug discovery, and toxicity testing. (2) Organs-on-chips for precision/personalized medicine.
Yu-Fen Chang, Ph.D
President
GenomeFrontier Therapeutics, Inc.
​​CAR-T cell therapy is a gene therapy in which patients’ white blood cells are genetically engineered to fight their own cancer.  Achieving more than 90% remission rate in patients with advanced blood cancers, this innovative immunotherapy offers new hope to dying children and adults with advanced blood cancers.  Though powerful in treating advanced blood cancers, conventional CAR-T is futile in fighting solid tumors due to the drawbacks and limitation imposed by the viral vectors used in CAR-T cell engineering.  GenomeFrontier is poised to change the outlook for patients with otherwise incurable advanced solid cancers by confronting this very challenge with bold solutions using our core technologies including Quantum pBAc, a revolutionized non-viral genetic system capable of loading 30 times more genes than the viral method and an innovative cell culture system designed for expending engineered CAR-T cells to a therapeutic quantity while maintaining its potency.  With these revolutionary technologies, we are developing universal super CAR-T therapies for solid cancers which are virus-free, reversible, and potent enough for treating a wide-range of cancers in a much safer fashion than the conventional CAR-T therapies.
​Chiung-Yuan Wu
CEO
Elixiron Immunotherapeutics Inc.
Elixiron Immunotherapeutics Inc. is a pre-clinical stage company focused on the development of transforming immunotherapy to treat chronic hepatitis B and cancer.  Our lead product EI001 is a fully human monoclonal antibody ready for IND-enabling studies as a potentially first-in-class curative HBV immunotherapy.  For cancer immunotherapy, we are developing therapeutic antibodies targeting tumor microenvironment to reactivate anti-tumor immunity and block cancer metastasis. Elixiron is positioned to launch our first clinical trial and deliver one additional drug candidate for clinical development in 18 months.
Hung-Kai Chen, M.D., Ph.D.
CEO
Meeting Agenda:

Agenda
08:30-09:00
Registration & Breakfast
09:00-09:15
Welcome Remarks:
‧Herbert Wu, PhD, President, Development Center for Biotechnology
‧Crystal Sung, PhD, President, Monte Jade New England
09:15-09:30
Opening Remarks by Guest of Honor:
‧Deputy Minister Fong-Chin Su, PhD, Chief Executive Officer, Taiwan Biomedical Development Board
09:30-10:00
Keynote: Powering the Future of Healthcare by Empowering Global Entrepreneurs
‧Michael LaRhette, President, MassChallenge
10:00-10:20
Taiwan Biobank for the Health of Future Generations
‧Chen-Yang Shen, PhD, Chief Executive Officer, Taiwan Biobank
10:20-10:30
Coffee Break
10:30-11:00
Startup Ecosystem Panel Discussion – “Fostering Entrepreneurship and Innovation”
‧Moderator: Herbert Wu, Development Center for Biotechnology
‧David Lucchino, Chairman of Massachusetts Biotechnology Council
‧Johnsee Lee, Chairman, Taiwan Bio Industry Organization
11:00-12:00
Technology Showcase: Precision Medicine & Digital Health
‧ACT Genomics, Mao Ying Genetech, ASUS Life Corporation, Augmented Intelligence, Funique VR Studio, Bio Preventive Medicine, Lumistar Biotechnology, GenomeFrontier Biosciences, Elixiron Immunotherapeutics
12:00-13:00
Luncheon
13:00-13:10
Welcome Remark:
‧Shaoyu Chang, Investment Manager, VI Ventures
13:10-13:50
Keynote: JJI & JLABS – Partnering Globally in Healthcare Innovation
‧Kate Merton, PhD, Head of JLABS at NYC & Boston - Johnson & Johnson Innovation
14:00-14:20
The Advantages of Taiwan's Capital Market
‧Fulung Ko, Chief Administrative Officer, Taipei Exchange (TPEx)
14:30-15:15
VC Panel Discussion - "Building Cross-Border Partnerships"
‧Moderator: Joan Lau, Managing Partner, Militia Hill Ventures
‧Akhil Saklecha, General Partner, Artiman Ventures
‧Greg Sieczkiewicz, Managing Director, Chief IP Counsel, MPM Capital
‧Christopher Kim, Managing Partner, Novatio Ventures
‧Kevin Chu, Associate, F-Prime Capital Partners
15:15-16:00
Corporate Panel Discussion - "Cross-Sector Innovations in Healthcare"
‧Moderator: Patrick DeCourcy, Principal Program Manager, Global Medical Affairs, Immunology, Sanofi Genzyme
‧Vikas Goyal, Associate, SR One
‧Hyuk-Jeen Suh, Head of Samsung Ventures East Coast
‧Michael Sierra, Vice President, LEO Science & Tech Hub
‧Alicia Irurzun Lafitte, Principal, M Ventures
16:00-16:45
Academia-Industry Panel Discussion - "Fostering a Robust Ecosystem"
‧Moderator: Jeng-Shin Lee, Chief Scientific Officer at AB Biosciences
‧Mary Ann Picard, Director of Operations, M2D2 @ UMass
‧Patrick Rivelli, Director of Life Sciences Track, MIT Alumni Angels
‧Ying Tam, Head of Healthcare, MaRS Ventures
‧Joel Berniac, President, CEO and Co-Founder, Akrivis Technologies
16:45-16:50
Closing Remarks
‧Leon Chen, Vice President, Monte Jade New England
16:50-18:00
Networking
Title: US-Taiwan Night 2018: AI in Healthcare 
Date & Time: 5:30 pm - 9 pm, June 6th
Venue: Boston Marriott Cambridge
Registration:  https://twbionight.eventbrite.com/

Dear CABA Members and Friends,

We cordially invite you to attend at the upcoming CABA/CBA 2018 Biopharma Forum – “Simcere Night”. The event will be held at Harvard Medical School’s Joseph B. Martin Conference Center (77 Avenue Louis Pasteur, Boston, MA 02115) from 5:30 PM to 8:30 PM on Tuesday, June 5, 2018.

As non-profit organizations based in Boston and Washington DC, respectively, Chinese-American BioMedical Association (CABA) and China Biopharmaceutical Association (CBA) strive to facilitate the communication of the latest advances in biomedical research and development; to assist in the exploration of new biotech/pharmaceutical market opportunities in the US and China; and to promote member career development and community service. Since inception, CABA and CBA have evolved into some of the most active and engaging Chinese American professional organizations locally in the greater Boston and DC Area, nationwide in the US and overseas in China.

For the upcoming 2018 Biopharma Forum, we expect to have 100+ prominent executives, investors, scientists, officials from biopharmaceutical companies, leading research institutions, venture capital investors, entrepreneurs and regulatory agencies from both US and China to come together to discuss the current state and future trend of the life science industry.

美中生物醫藥協會第11屆年會暨波士頓生物醫藥論壇 5/1

🏨Boston Marriott Newton
📍2345 Commonwealth Ave, Newton, MA 02466
🕙8:00 AM to 9:00 PM on Saturday, May 19, 2018.



                 SPEAKERS            

   
Bill Fodor, PhD
Chief Scientific Officer
 Biostage 

Felix Hsu, MBA
SVP
Head of WuXi Advanced Therapies

Geoff Mckay
CEO
 Avrobio 

Birgit Schultes, PhD
VP of Immunology
 Intellia Therapeutics Inc 

Yide Alan Jiang, PhD
Chief Strategic Officer
Xtalpi Inc.

Xiaole Shirley Liu, PhD
Professor of Statistics, Biostatistics, and Computational Biology
Dana-Farber Cancer Institute, Harvard T.H. Chan School of Public Health

Tong-Tong Xue, PhD
CEO of Kelun Bo-Tai Biological Company
Vice President of Kelun Pharmaceutical Research Institute

Cheryl Cui, PhD
Partner, Nest.Bio Ventures
 Venture Partner, Venture Health

Sean Fu, PhD
Vice President of Luye Global R&D
President of Luye Boston R&D LLC  

Debra Yu, MD
Managing Director, Head of Cross-Border Healthcare Investment Banking
China Renaissance

Johnson Zhang, MBA
Vice President & General Manager, Perkin Elmer APAC

John Xu, PhD, MBA
Sr Vice President of Strategic Alliance
Abpro

2018哈佛华人生物医学年会报道
哈佛医学院华人专家学者联合会(HMS-CSSA)经历十载春秋,已经成为哈佛医学院专家学者不可或缺的交流平台之一。一年一度的哈佛华人生物医学年会(以下简称“年会”)更是HMS-CSSA每年的重头戏。2018年5月5日,年会如期在在哈佛医学院波士顿儿童医院Folkman Auditorium举办。本次年会一共分为4个部分,内容涵盖了Development and Epigenetics(发育和表观遗传学)、Signaling Pathway(信号通路)、Cancer Biology(肿瘤生物学)和 Deciphering Protein Structure and Genome Sequence(蛋白结构解析和基因组测序),堪称是一场学术盛宴。现场的火爆程度不用赘述,单从报名满额的速度就能一瞥虚实。知识的力量是无限的,但交流的机会是有限的,为了不让赶不到会场的朋友们留下遗憾,协会还特意设立了分会场和网络直播,让知识能够更好的分享给大家。
大会现场座无虚席
主持人毛萍萍
晨光初起,协会成员和志愿者们就陆续忙碌起来,准备迎接广大学者的到来。与会者一个个入场,时钟也一步步走向开幕。在HMS-CSSA会长杨淞博士简单的致辞之后,哈佛医学院院长 George Daley 教授代表哈佛医学院向广大学者致以问候。他强调了科学对于人类健康的重大贡献,也重点强调了科学工作者们间交流和紧密合作的重要性,以及科学工作者的社会责任。
HMS-CSSA会长杨淞
开场致辞之后,哈佛医学院院长George Daley在第一个主题报告中,介绍了他带领的课题组攻克了20年来造血干细胞体外再生的难题,成功通过过表达7个转录因子将人工诱导干细胞重编程为造血干细胞的过程。该造血干细胞可以在体内自我更新并分化为红细胞和白细胞等各种血液细胞,为需要骨髓移植的患者带来了希望。
哈佛医学院院长George Daley精彩演讲
会议第二位报告人是来自加州大学圣迭戈分校的付向东教授,他大家介绍了他实验室开发的用于从全基因组水平研究RNA和染色质相互作用的Grid-seq技术。通过该技术他们构建了不同细胞类型的染色质结构和基因组的三维构型,并发现了一系列在启动子-增强子网络中的关键调控节点。
加州大学圣迭戈分校付向东教授和哈佛医学院张毅教授
来自Whitehead研究所的美国科学院院士Rudolf Jaenisch教授首先介绍了他们实验室开发的甲基化报告系统,通过该系统可以在单细胞的水平下通过荧光衡量某一个基因启动子区的甲基化水平。接下来,他向我们介绍了使用改造后的CRISPR系统修改FMR1基因甲基化水平的工作,该工作为治疗脆性X染色体综合症提供了新的方向。
美国科学院院士Rudolf Jaenisch教授
哈佛医学院附属波士顿儿童医院的贺熹教授向大家讲述了他实验室最近一系列研究Wnt信号通路对于动物胚胎发育调控的分子机制,特别是他们最近发现的Tiki和Notum两个新的Wnt调控蛋白,这两个蛋白通过直接对Wnt蛋白的化学修饰来调控Wnt通路的活性。
波士顿儿童医院贺熹教授和王大之教授
William Pu教授来自哈佛医学院附属波士顿儿童医院,他生动地为大家介绍了“heart-on-a-chip”,这个技术是利用工程学手段将心肌细胞固定在芯片,并且可以模拟心脏功能特点。他们组利用该工具研究了包括Barth综合症和心律失常等心脏相关疾病的致病机制并筛选了可能的治疗药物。
波士顿儿童医院 William Pu教授
赵瑾(Jean Zhao)教授阐述了她对于结合靶向药物和目前迅速崛起的免疫疗法在癌症治疗中的最新发现及独到见解。她的研究显示对细胞周期蛋白依赖性激酶CDK4/6的抑制可增强肿瘤细胞的抗原呈递,并增加肿瘤内T细胞浸润,同时减少调节性T细胞(T-regs)。她同时向我们展示了联合使用p110beta 和 PD-1抑制剂在前列腺癌中的显著抗癌效果及相关最新发现。
丹娜法伯癌症研究院赵瑾(Jean Zhao)教授和祁军教授
来自哈佛医学院附属Beth Israel Deaconess医学中心的魏文毅教授为我们介绍了S6K1的最长可变剪切体p85在癌症中的重要作用。他实验室最近发现p85作为一种癌细胞分泌蛋白,可以在细胞系和小鼠模型中促进癌细胞的生长和转移。

Beth Israel Deaconess医学中心魏文毅教授
Nathanael Gray博士分享了一种新的靶向治疗癌症的策略,通过双功能小分子借用细胞自身的泛素化降解系统,以及以此技术为基础的dTAG技术,精准的定点降解靶标蛋白,来达到癌症治疗的目的。同时他们发现使用降解技术可以有效提高药物选择性,在CDK9的降解工作中他们完美解决了CDK9和CDK家族其他蛋白的选择性问题,为靶向治疗提供了新的机会。

丹娜法伯癌症研究院Nathanael Gray教授
王家槐教授从结构生物学的视角为我们阐释了神经生长因子Netrin-1与Draxin与神经受体的相互作用机制。这两个神经生长因子分别与同一神经受体DCC相互作用会引发吸引与排斥两种不同的反应。通过对三组复合物的X射线晶体结构研究及相关的神经生物学研究,揭示了通过 DCC-Draxin-Netrin-1-DCC 搭建起的桥梁形成神经细胞接触与生长的分子机制。
哈佛医学院王家槐老师和刘小乐教授
大会最后由美国国家科学院,国家医学院和文理科学院院士谢晓亮教授以生动幽默的演讲回顾了自己在哈佛大学二十年的科研经历。从早期的单分子酶学,到近期的单细胞全基因组学,谢晓亮教授向大家介绍了他在基础科研和临床应用两方面的重要工作成果。报告最后,他还详细阐述了他的研究组在单细胞三维基因组结构和单细胞转录调控模块领域的最新研究成果。谢晓亮教授的这些研究不但对于理解生物中心法则的运作方式有重要贡献,而且还极大地促进了包括产前筛查等人类健康领域的发展。谢晓亮教授将于近期赴北京大学全职工作,他此次和大家分享的科研和人生经历无疑为在座的年轻学者们提供了最为宝贵的经验。
三院院士谢晓亮教授
最后是2018年哈佛华人生命医学优秀学术奖颁奖典礼。涌金集团特别赞助了本年度学术奖的奖金,以激励哈佛的年轻学者们。 经过激烈的竞争,十二位在哈佛工作的优秀学者获得今年的学术奖。哈佛医学院刘小乐教授和谢晓亮教授为获奖者颁发了证书与奖金,以嘉奖他们在多个生物医学领域的出色成果。
2018年涌金哈佛华人生命医学优秀学术奖颁奖典礼
在热烈的掌声中,年会也落下帷幕。学术的宴席虽然会散场,但相信知识的延伸就像直线一样没有终点。这也是HMS-CSSA举办年会的意义,希望在这条直线上留下印记,能够让学者们驻足交流。从2010年第一届年会以来,HMS-CSSA就秉承着自由开放的原则,让每个人都能感受到学术的魅力。这也是为什么每次都有众多学术带头人前来分享,让年会成为中美生命科学和医学领域的重要学术会议之一的原因。学术无国界,思想无界限,希望哈佛华人生物医学年会能够越办越好,更好的为广大学者们服务!
2018哈佛华人生物医学年会组织者合影
撰稿:黄岳,岳宏,蔡文青,曹婵,周慡,段松伟
摄影:黄岳,杜广延
Harvard Chinese Life Science Annual Symposium 2018
May 5th, 2018
Folkman Auditorium, Enders Building, Boston Children’s Hospital320 Longwood Ave, Boston, MA 02115
Organizing Committee
Harvard Medical School - Chinese Scientists & Scholars Association(HMS-CSSA)
Song Yang, Qiong Ye, Linchang Huang, Wenqing Cai, Wei Li, Bin Li, Xiaoqing Wang, Shuxi Qiao, Hong Yue, Jingyu Peng, Yue Zhang, Xianrui Yang, Miao Liu, Chan Cao, Yiming Zhou, An Xiao, Yang Zhang, Yue Huang, Lijie Xing, Mohui Wei, Shengqing Gu, Tao Wang, Xiaofeng Li, Zhengnian Li, Hui Liu, Jiye Liu, Junlin Guo, Pingping Mao, Su Wang, Shuang Zhou, Jinmiao Chen, Songwei Duan, Yanan Qi
Organizing Committee Advisors
Jianzhu Chen, Professor, Massachusetts Institute of Technology
Chuan He, Professor, University of Chicago
Xi He, Professor, Boston Children’s Hospital, Harvard Medical School
Zhigang He, Professor, Boston Children’s Hospital, Harvard Medical School
Frank Hu, Professor, Harvard T.H.Chan School of Public Health 
Xiaole Shirley Liu, Professor, Dana-Farber Cancer Institute / Harvard T.H.Chan School of Public Health 
Hongbo Luo, Associate Professor, Harvard Medical School
William Pu, Professor, Boston Children’s Hospital, Harvard Medical School
Yang Shi, Professor, Boston Children’s Hospital, Harvard Medical School
Jiping Wang, Assistant Professor, Brigham and Women’s Hospital, Harvard Medical School
Hao Wu, Professor, Boston Children’s Hospital, Harvard Medical School
Yingzi Yang, Professor, Harvard School of Dental Medicine
Junying Yuan, Professor, Harvard Medical School
Yi Zhang, Professor, Boston Children’s Hospital, Harvard Medical School
Jean Zhao, Professor, Dana-Farber Cancer Institute, Harvard Medical School
Invited Speakers
George Daley, MD, PhDHarvard Medical School, Boston Children’s Hospital
Dr. George Q. Daley seeks to translate insights in stem cell biology into improved therapies for genetic and malignant diseases. Important research contributions from his laboratory include the creation of customized stem cells to treat genetic immune deficiency in a mouse model (together with Rudolf Jaenisch), the differentiation of germ cells from embryonic stem cells (cited as a “Top Ten Breakthrough” by Science magazine in 2003), and the generation of disease-specific pluripotent stem cells by direct reprogramming of human fibroblasts (cited in the “Breakthrough of the Year” issue of Science magazine in 2008). As a graduate student working with Nobel Laureate Dr. David Baltimore, Dr. Daley demonstrated that the BCR/ABL oncogene induces chronic myeloid leukemia (CML) in a mouse model, which validated BCR/ABL as a target for drug blockade and encouraged the development of imatinib (GleevecTM; Novartis), a revolutionary magic-bullet chemotherapy that induces remissions in virtually every CML patient. Dr. Daley’s recent studies have clarified mechanisms of Gleevec resistance and informed novel combination chemotherapeutic regimens.
Dr. Daley received his bachelor's degree magna cum laude from Harvard University (1982), a Ph.D. in biology from MIT (1989), and the M.D. from Harvard Medical School, where he was one of twelve individuals in the school’s history to be awarded the degree summa cum laude (1991). He served as Chief Resident in Internal Medicine at the Massachusetts General Hospital (94-95) and is currently a staff physician in Hematology/Oncology at the Children's Hospital and the Dana Farber Cancer Institute, and a member of the Hematology Division of the Brigham and Women’s Hospital in Boston. He has been elected the National Academy of Medicine(NAM), the American Society for Clinical Investigation, the American Association of Physicians, and the American Pediatric Societies, and is a fellow of the American Academy of Arts and Sciences (AAAS) and the American Association for the Advancement of Science.
  
Xiang-Dong Fu, PhDDepartment of Cellular and Molecular Medicine, University of California, San Diego
Dr. Fu’s laboratory is interested in molecular and cell biology of RNA metabolism and regulation in higher eukaryotic cells. Current research interests in the Fu lab include the regulation of alternative splicing, functional RNA elements in mammalian genomes, transcription/splicing coupling, nuclear architecture, and cellular reprogramming. Dr. Fu was a major contributor for co-discovery of SR proteins, a family of RNA binding proteins involved in constitutive and alternative pre-mRNA processing. His laboratory was the first to identify a family of kinases specific for SR proteins and demonstrated that these kinases are critical for transducing external and intracellular signals to regulate alternative splicing in the nucleus. Dr. Fu's group elucidated a series of regulatory mechanisms for splice site selection in mammalian cells and developed multiple key technologies for high throughput analysis of gene expression, mRNA isoforms, and genomic interactions. Dr. Fu's current research is focused on integrated regulation of gene expression at transcriptional and post-transcriptional levels. Dr. Fu's contribution to biomedical science has been recognized by selection for the Searle Scholar award (1994) and the Leukemia and Lymphoma Society Scholar award (1997) and election to Fellow of American Association for the Advancement of Science (2010).
Dr. Fu is a Professor of Cellular and Molecular Medicine at University of California, San Diego. Dr. Fu received his MS degree in Virology from Wuhan University, China in 1982, PhD degree in Biochemistry from Case Western Reserve University in 1988 (via the CUSBEA program), and postdoctoral training at Harvard from 1988 to 1992. Dr. Fu joined the faculty of University of California, San Diego in 1992 (Assistant Professor, 1992-1998; Associate Professor, 1998 to 2002; and Full Professor, 2002-present).

Rudolf Jaenisch, PhD
Founding Member of Whitehead InstituteDepartment of Biology, MIT
Dr. Jaenisch lab’s expertise is in epigenetics, reprogramming and stem cells. Dr. Jaenisch began his research career as a pioneer making transgenic mice, some of which have produced important advances in understanding cancer, neurological and connective tissue diseases, and developmental abnormalities. These methods have been used to explore basic questions such as the role of DNA modification, genomic imprinting, X chromosome inactivation, nuclear cloning, and, most recently, the nature of stem cells. In addition, using mice as a model and a technique called “altered nuclear transfer,” Dr. Jaenisch has demonstrated that it is possible to procure embryonic stem cells without harming a viable embryo. More recently he has demonstrated that somatic cells can be reprogrammed in vitro to pluripotent ES-like cells and that these cells are suitable to correct both genetic and induced defects in mice by transplantation therapy. Using this technique for turning skin cells into stem cells, the lab has been able to cure mice of sickle cell anemia -- the first direct proof that these easily obtained cells can reverse an inherited disease.
Dr. Jaenisch is a Professor of Biology at MIT and a founding member of the Whitehead Institute for Biomedical Research. He has been granted numerous awards from organizations across the world. He is a pioneer of transgenic science, in which an animal’s genetic makeup is altered. Jaenisch has focused on creating genetically modified mice to study cancer and neurological diseases. Dr. Jaenisch received his doctorate in medicine from the University of Munich in 1967. He became a postdoc at the Max Planck Institute in Munich, studying bacteriophages. He left Germany in 1970 for research positions at Princeton University, Fox Chase Institute for Cancer Research and the Salk Institute. He returned to Germany in 1977 to become the head of the Department of Tumor Virology at the Heinrich Pette Institute at the University of Hamburg. He arrived at MIT in 1984. He participated in the 2005 science conference on human cloning at the United Nations and serves on the science advisory boards of the Genetics Policy Institute and Stemgent.

Xi He, PhDBoston Children’s Hospital, Harvard Medical School
Dr. He’s laboratory seeks to understand the molecular basis of cell-to-cell communication, and how this communication regulates embryonic and neural development in vertebrates. Dr. He is also interested in learning how defective regulation of cell communication causes human cancers and diseases. In particular, Dr. He is investigating signaling mechanisms employed by secreted growth factors of the Wnt family, which play critical roles in establishing the anterior-posterior axis of the embryo and underlie the formation of head versus trunk regions during early embryogenesis. Wnt signaling pathways are also pivotal in the development of human cancers--as several key Wnt signaling components are encoded by human oncogenes or tumor suppressor genes--and in the pathogenesis of many human diseases, such as osteoporosis and degenerative disorders. Dr. He aims to identify molecular components of Wnt signaling pathways and the mechanisms by which Wnt pathways are activated and governed during embryonic development and human tumorigenesis. 
Dr. He received his bachelor’s degree in engineering at Huazhong University of Science and Technology (HUST), Wuhan, China, and Ph.D. in Dr. Michael G. Rosenfeld’s lab at University of California, San Diego (UCSD). After his postdoctoral training with Dr. Harold Varmus at National Cancer Institute (NCI), Dr. He became an Assistant Professor at Boston Children’s Hospital in 1997. He was promoted to professor in 2007. Dr. He was a Pew Scholar, a Klingenstein Fellow, a W. M. Keck Distinguished Young Scholar and a Leukemia and Lymphoma Society Scholar. Dr. He received the Young Investigator Award from the Society of Chinese Bioscientists in America (SCBA) in 2004, and holds a Chang Jiang Guest Professorship and 1000 Talent Plan (B) Professorship at HUST. Dr. He is an elected Fellow of American Association for the Advancement of Science and an American Cancer Society Research Professor. He has served on numerous review and advisory boards in academia and the biopharmaceutical industry in the USA, Canada, EU, UK and China.

William Pu, MDBoston Children's Hospital, Harvard Medical School
The Pu lab is interested in the regulation of gene expression and cell lineage specification in heart development, disease, and regeneration using various technologies including genetically engineered mice, conditional gene inactivation, genome-wide chromatin occupancy analysis, and RNA expression profiling. The major goals of Dr. Pu's research include: 1. To understand the transcriptional network regulating heart development and disease; 2. To understand cell lineage specification in heart development and regeneration; 3. To understand genetic contributions to congenital heart disease.
Dr. Pu received an MD from Harvard Medical School. He completed his internship, residence, and pediatric cardiology training at Boston Children’s Hospital. Dr. Pu has been an independent PI since 2004 and has an established track record of innovation in cardiovascular biology. Dr. Pu has 19 successful postdoctoral fellow “alumni”. Among those, 12 remain in academic medicine, 11 have faculty appointments, and 8 are PIs of independent research labs in Europe, North America, and China. Dr. Pu is also the contact PI of the Boston Children’s Hospital Department of Cardiology T32 training grant and the Director of Basic and Translational Cardiovascular Research for the Department of Cardiology at Boston Children’s Hospital.

Jean Zhao, PhDDana-Farber Cancer Institute, Harvard Medical School 
Dr. Zhao’s research centers on understanding kinase signaling pathways in cancer. Her laboratory has pioneered a new front for understanding signal transduction by integrating mouse genetics, chemical biology and immunology in the field of translational cancer research. Her productive and insightful work on deciphering the role of PI3-kinase isoforms and the cyclin D1-CDK4/6 pathway in cancer not only addresses important basic science questions, but also has had a significant clinical impact. By providing a mechanistic understanding of the synergies gained for targeting PI3K isoforms and CDK4/6 in combination with immune checkpoint blockade in cancer, her lab has guided the design of current clinical trials of integrating immunotherapy and targeted therapy both here at DFCI and internationally. 
Dr. Jean Zhao is a Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School (HMS) and Dana-Farber Cancer Institute (DFCI). Dr. Zhao has been widely recognized for her innovation and excellence in the field. After obtaining her Ph.D. degree with honors from Tufts University School of Medicine in Boston, Dr. Zhao completed her postdoctoral training in the laboratory of Dr. Thomas M. Roberts at DFCI. Dr. Zhao began her independent research at HMS and DFCI in 2006. Her honors and awards include the Career Development Awards from NIH/NCI, the V Scholar Award, the Starr Foundation Award and, recently, the Outstanding Investigator Award from NIH/NCI. Dr. Zhao serves as a member on multiple scientific boards and committees, including the Executive Committee for Research and the Committee for Women Faculty at DFCI, the Steering Committee of Breast Cancer at DF/Harvard Cancer Center and the Advisory Council of the National Brain Tumor Society.

Wenyi Wei, PhDBeth Israel Deaconess Medical Center, Harvard Medical School
The major focus of research in Dr. Wei’s laboratory is aimed at understanding how APC and SCF activities contribute towards cell cycle regulation and subsequent tumor formation. More specifically, Dr. Wei is interested in elucidating the underlying mechanisms that define the oscillation of APC and SCF activity in different cell cycle phases. Currently, he is pursuing the underlying mechanisms that timely regulate APC/Cdh1 activity in different cell cycle phases. Additionally, Dr. Wei is also interested in understanding whether other layers of crosstalk between the APC and SCF complex exist. Furthermore, Dr. Wei would like to identify novel downstream targets for both APC and SCF complexes, which will help pinpoint their functions in both cell cycle control and tumor formation. To this end, Dr. Wei has developed biochemical purification approaches that would allow him to identify novel downstream targets for APC/Cdh1 and SCF/Fbw7 complexes. In addition, he is also interested in defining the tumor suppressor function of Cdh1 utilizing conditional Cdh1 knockout mice. To achieve these goals, Dr. Wei’s lab will use multidisciplinary approaches including biochemical and genetic analysis. 
Dr. Wenyi Wei received his B.A. degree from Shandong University in 1993 and then obtained his M.S. training in Chinese Academy of Science from 1993 to 1996. Afterwards Dr. Wei received his Ph.D. training in the Department of Molecular Biology, Cell Biology & Biochemistry (MCB) at Brown University and his postdoctoral training in the laboratory of Dr. William Kaelin, Jr. at DFCI and Harvard Medical School. Dr. Wei became independent from 2006 in Department Pathology at Beth Israel Deaconess Medical Center and Department of Pathology at Harvard Medical School. 


Nathanael Gray, PhD
Dana-Farber Cancer Institute, Harvard Medical School
Dr. Nathanael Gray’s research utilizes the tools of synthetic chemistry, protein biochemistry, and cancer biology to discover and validate new strategies for the inhibition of anti-cancer targets. Dr. Gray’s research has had broad impact in the areas of kinase inhibitor design and in circumventing drug resistance. Dr. Gray has established a discovery chemistry group that focuses on developing first-in-class inhibitors for newly emerging biological targets, including resistant alleles of existing targets, as well as inhibitors of well-validated targets, such as Her3 and RAS, that have previously been considered recalcitrant to small molecule drug development. Amongst the additional notable achievements of Dr. Gray’s research laboratory are: development of the first T790M selective EGFR inhibitors, ATP-competitive mTor inhibitor, Torin1, and its use to discover that rapamycin is an incomplete inhibitor of mTOR; development of the first inhibitors of ERK5 (BMK1), CDK7 and CDK12. 
Dr. Gray received his PhD in organic chemistry from the University of California at Berkeley in 1999 after receiving his BS degree with the highest honor award from the same institution in 1995. After completing his PhD, Dr. Gray was recruited to the newly established Genomics Institute of the Novartis Research Foundation (GNF) in San Diego, California. In 2006, Dr. Gray returned to academia and accepted a faculty appointment at the Dana Farber Cancer Institute and Harvard Medical School in Boston. Dr. Gray’s scientific contributions have been recognized through numerous awards including the Career Award of the National Science Foundation in 2007, the Damon Runyon Foundation Innovator award in 2008, the American Association for Cancer Research for Team Science in 2010 and for Outstanding Achievement in 2011 and the American Chemical Society award for Biological Chemistry in 2011.

Jiahuai Wang, PhDDana-Farber Cancer Institute, Harvard Medical School
Dr. Wang’s lab has been focusing on structures of cell surface receptors that play critical roles in the immune system and nervous system. In collaboration with colleagues within Dana-Farber and Harvard Medical School, the Wang lab has worked out structures of a number of key immune molecules, including T cell receptors, MHC molecules, co-receptors and their interacting complexes. His group has also determined structures of many cell adhesion molecules, such as CD2, CD58, Cadherin, ICAM family members and the complexes with their interacting partners. More recently he begins to turn his interests into neuronal receptors. Most recently in collaboration with a group at EMBL, Hamburg, Dr. Wang has determined the structure of netrin-1 in complex with DCC, uncovering the molecular mechanism of netrin-1 bi-functionality, a long-standing puzzle in the neuroscience field.
Dr. Jiahuai Wang obtained his B.A from the University of Science and Technology of China in 1963 and an equivalent Ph.D. from the Beijing Biophysics Institute, Chinese Academy of Sciences in 1979. He had worked in Biophysics Institute in the period of 1963-1979. During 1979-1982, he was a visiting scholar at University of Wisconsin at Madison and at Harvard University, the Department of Biochemistry and Molecular Biology. In 1982-1988 he was back in Beijing Biophysics Institute, promoted to Associate Professor and later Professor. He served as director of Protein Crystallography Department there in 1987-1988. He was appointed as a member of National 863 Committee of Biotechnology of China in 1986-1990. He came to the United States again late in 1988 working at Harvard Medical School, the same department till 1996 before moving to Dana-Farber Cancer Institute as a Principal Investigator. In 2001, he was promoted as an Associate Professor of Pediatrics and Biological Chemistry and Molecular Pharmacology at Harvard Medical School.

Xiaoliang Sunney Xie, PhDDepartment of Chemistry and Chemical Biology, Harvard University
Dr. Xiaoliang Sunney Xie received a B.S. from Peking University in 1984, and his Ph.D. from the University of California at San Diego in 1990, followed by a short postdoctoral experience at the University of Chicago. In 1992, Xie joined Pacific Northwest National Laboratory, where he later became a Chief Scientist. In 1999, he was appointed Professor of Chemistry at Harvard University. He was the first full professor at Harvard University from the People's Republic of China since China's reform in 1978. He is currently the Mallinckrodt Professor of Chemistry and Chemical Biology at Harvard, and the Director of Beijing Advanced Innovation Center for Genomics at Peking University.
Xie is among the first to conduct fluorescence studies of single molecules at room temperature in the early 1990s. He has made major contributions to the emergence of the field of single-molecule biophysical chemistry and its application to biology. His team also pioneered the development of coherent Raman scattering microscopy and single cell whole genome sequencing.
His honors include the Albany Prize in Medicine and Biomedical Research, the U. S. Department of Energy E. O. Lawrence Award, the Biophysical Society’s Founders Award, the National Institute of Health Director’s Pioneer Award, the Sackler Prize for Physical Sciences and the American Chemical Society’s Peter Debye Award. Xie is a fellow of the American Academy of Arts and Sciences and a member of the National Academy of Sciences. He is also an honorary fellow of the Chinese Chemical Society and has received scholarly awards from China, Germany and Israel. 


 2017年对全球医疗卫生事业是意义非凡的一年。中国于今年启动了“健康中国2030长期规划”,政府与民间正如火如荼地投入到医疗大健康的领域;美国的政府与民间也在医疗健康领域积极寻求变革策略。本届峰会以“大健康,大趋势”为主题,将重点探讨:

      1)全球卫生健康面临的复杂挑战
      2)健康和医学科学技术的大趋势
      3)健康和医疗服务创新大趋势

我们诚挚邀请您参与这场中美医疗界的年度盛会,共同探讨未来的健康医疗大趋势!峰会现开放注册,注册请扫描文末二维码。

部分演讲嘉宾:
Ezra Vogel
哈佛大学社会科学荣誉教授
主旨演讲
William Haseltine
ACCESS健康国际有限公司董事长兼总裁
Arthur Kleinman
哈佛医学院社会医学人类学教授
刘远立
北京协和医学院公共卫生学院院长
Mark Elliott  
哈佛大学国际事务副教务长
Kyu Rhee
IBM Watson Health副总裁兼首席卫生官
Randall Moore
Mercy Virtual Health主席
 David Blumenthal
英联邦基金会主席
Robert Huckman
哈佛商学院工商管理教授
Donald Ingber
哈佛威士研究所创始主任
Alan Trager
公私伙伴关系倡议创始人兼主任; 清华大学PPP研究中心国际比较研究中心首席专家
孙喜琢 
深圳市罗湖医院集团总院长

Time:
Sep 9th (Saturday) 2017, 10am - 2pm
Location:
Dana Building 1620, Dana-Farbar Cancer Institute
450 Brookline Ave, Boston, MA 02215
Lunch will be provided

No comments:

Post a Comment